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SUMMARY
38-hydroxysteroid dehydrogenase (36-HSD) catalyses a series of obligatory 
biosynthetic steps in the synthesis of mineralocorticoids, glucocorticoids and sex 
steroids. Specifically, it converts the 38-hydroxysteroids pregnenolone, 
17-hydroxypregnenolone, dehydroepiandrosterone, and androstene 38,178-diol into 
the respective 3-ketosteroids: progesterone, 17alpha-hydroxyprogesterone, 
androstenedione and testosterone. In rodents at least three genes for 38-HSD have 
been found to be expressed. When analysed on southern blots, human DNA shows 
evidence of six or more sequences with homology to 38-HSD probes. So far, two 
highly homologous but distinct human genes have been cloned, encoding 36-HSD 
type I expressed principally in the placenta, and 38-HSD type II expressed in adrenal, 
ovary and testis. Though the type I and II enzymes differ in their kinetics in detail, 
they are both capable of converting the same A  ^substrates.
It has long been recognised that inherited defects of 38-HSD can result in congenital 
adrenal hyperplasia (CAH) and nonsense and frameshift mutations in the gene for 
38-HSD type II have recently been described in classical cases of severe CAH 
affected with salt-losing crises, deficiencies in glucocorticoid metabolism and 
incomplete masculinisation. A range of less severe phenotypes have also been 
ascribed to deficiencies of 38-HSD, including hypospadias, male 
pseudohermaphroditism, and late onset virilisation in women. In some cases these are 
associated with a degree of salt loss, in others salt handling is normal. It is not clear to 
what extent these different clinical phenotypes are due to different mutations in the 
same gene, or to mutations in other 38-HSD genes encoding enzymes with somewhat 
different functions.
This thesis describes the investigation of three families ( Ran, Sta, and Pfe ) affected 
with putative 38-HSD deficiency. The aim of this thesis was to identify the molecular
genetic basis of 38-HSD deficiency in each of the three families. I visited the 
laboratory of Professor D. A. Hopkinson and Dr. P. H. Johnson, MRC Human 
Genetics, Galton Laboratories, London to compare the use of several screening 
techniques for detecting mutations: chemical cleavage, temperature gradient gel 
electrophoresis ( TGGE ), and denaturing gradient gel electrophoresis ( DGGE ). 
DGGE was judged to be the most useful of these techniques and was subsequently 
used to search for mutations in the type I and type II genes for 38-HSD. More 
recently, automated DNA sequencing of the 38-HSD type II gene was carried out in a 
further attempt to detect mutations.
In family Ran the propositus, a 5 year old XY pseudohermaphrodite, was found to 
have a defect of steroid biosynthesis consistent with a partial deficiency of 38-HSD. 
There was no evidence of salt loss and no detectable abnormality of glucocorticoid 
metabolism. A mutation in the gene for 38-HSD type II was observed at codon 173 
(CTA->CGA), leading in the affected patient to the homozygous substitution of 
1 7 3 leu->arg The propositus' 2 year old XX sister was also 173^8/^8; she showed 
the biochemical signs of 38-HSD deficiency but was without clinical symptoms. The 
mutation segregated as an autosomal recessive. A number of family members 
heterozygous for the codon 173 substitution exhibited biochemical and clinical 
abnormalities though to a lesser degree than the two homozygous children.
Family Sta was characterised by two brothers both affected with hypospadias. Urinary 
steroid analysis indicated a partial deficiency of 38-HSD. One of the brothers also 
showed evidence of mild salt loss and demonstrated an impaired cortisol response to 
synacthen. No other members of the family were affected indicating an autosomal 
recessive condition. DGGE and subsequent DNA sequencing revealed a single point 
mutation in the gene for 38-HSD type II. A missense mutation at codon 100 ( AAT- 
>AGT ) resulted in the substitution of Asn for Ser. The mother and both of the 
brothers were heterozygous for this mutation. To date no evidence of mutation has
been detected in either the 38-HSD type I or 38-HSD type II genes of the father in 
family Sta.
Family Pfe contained four female members affected with varying degrees of 
dysmenorrhea and hirsutism. Despite a diagnosis of partial 38-HSD deficiency it was 
conclusively shown by use of polymorphic markers in 38-HSD types I and II that the 
disease phenotype did not co-segregate with either of the known 38-HSD genes. This 
finding has important implications for the future diagnosis of 38-HSD deficiency.
Future work on families Ran and Sta will involve the expression of the mutant alleles 
in vitro to determine the effect of each substitution on the activity of 38-HSD type II. 
As the hirsutism in family Pfe appears not to be caused by a deficiency in 38-HSD, 
future work may include the typing of family Pfe for a panel of polymorphic markers 
in candidate genes such as aromatase in an attempt to establish linkage.
During the course of this work a number of polymorphic markers and mutations were 
identified in both the type I and type II genes. These markers were used to determine 
the segregation of genes within each family. The markers were also used to show that 
the genes for 38-HSD types I and II are in close genetic linkage on chromosome 
lp l3 . In addition to polymorphisms and mutations in 38-HSD types I and II, a 
number of sequences homologous to 38-HSD were isolated by the use of DGGE. The 
possibility of a tightly clustered gene family raises the possibility that in some cases 
of 38-HSD deficiency, mutations may be due to unequal crossing over or to gene 
conversion, as has been observed in several other gene clusters. It is hoped that the 
use of somatic cell hybrids will allow the mapping of 38-HSD homologues that have 
been detected by DGGE, to chromosome lpl-2 and hence to determine their linkage 
relationships ( if any ) to 38-HSD types I and n.
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1INTRODUCTION
Hormones are widely distributed being found in almost all living cells. Hormones 
exert wide ranging effects on the activity of the body in response to changes in both 
the internal and external environment. Some hormones act locally i.e. they are 
secreted and exert their effect within individual tissues, for example, growth factors. 
Other hormones have a long range effect, reaching their target tissues by diffusing 
into the circulation. From the chemical standpoint there are three groups of hormones. 
Firstly, there are derivatives of the amino acid tyrosine, secondly, peptide and protein 
hormones and thirdly, steroid hormones. Cholesterol is the natural precursor of all 
steroid hormones. The biochemical pathway for steroid biosynthesis starts from 
acetate, via mevalonate and squalene to cholesterol. Though steroid hormones are 
present in almost all living cells, organs such as the adrenals, testes, ovaries and 
placenta are highly specialised in the metabolism of cholesterol and the synthesis of 
steroid hormones. According to current concepts, the biosynthetic pathways in all 
endocrine organs that form steroid hormones are similar, the organs differing from 
one another only in the enzyme systems they express. For example, some tissues are 
capable of metabolising cholesterol whereas other tissues require to be supplied with 
steroid intermediates which they can then metabolise.
Adrenal steroidogenesis
The adrenals are situated at the superior pole of each kidney and consist of two 
endocrine organs, one surrounding the other ( Fig la, b, c ). The inner adrenal 
medulla secretes the catecholamines adrenaline, noradrenaline, and dopamine, which 
are involved in preparing the individual to deal with emergencies. The adrenal cortex 
secretes steroid hormones. The adrenal cortex is divided into three zones. The outer 
zona glomerulosa is made up of whorls of cells which often appear discontinuously
22 m m
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Figure 1: The adrenal glands ( adapted from R.V.Krsic 1991)
KEY: kidneys - K; suprarenal glands - AG; capsule - CA; cortex - C; 
medulla - M; medullary veins - MV; suprarenal vein - SV; suprarenal 
arteries - SA; nerve fascicles - NF; lymphatic vessels - LV; zona 
glomerulosa - ZG; zona fasciculata - ZF; zona reticularis - ZR; chromaffin 
cells - CC; ganglion cells - GC; subendothelial cushions - IC; capsular 
plexus - CP; capillaries - Cap; arteriolae perforantes - AP.
under the glandular capsule. The zona fasciculata is a wide zone consisting of 
columns of cells separated by venous sinuses. The cells of the zona fasciculata have 
abundant reserves of lipid. The inner portion of the zona fasciculata merges into the 
more compact zona reticularis. The blood flow in the adrenal cortex is large, as it is in 
most endocrine glands, and it is thought that pooling and reflux of blood carrying 
secretory products may be significant for control of steroidogenic activity in different 
locations. Arterial blood reaches the adrenal from many small branches of the phrenic 
and renal arteries and the aorta. The blood then proceeds from the subcapsular region 
to the central portal vein (Dobbie et al. 1968).
Three classes of steroids are produced in the adrenal cortex: mineralocorticoids, 
glucocorticoids and sex steroids. The mineralocorticoids are essential to the 
maintenance of sodium balance and extracellular fluid volume. The production of the 
major mineralocorticoid aldosterone is limited to the zona glomerulosa. 
Glucocorticoids have widespread effects on the metabolism of carbohydrate and 
protein. Cortisol, the principal glucocortcoid, is produced in the zona fasciculata 
(Nussdorfer 1986). The sex steroids, androgens and oestrogens, are involved in the 
differentiation of the genital ducts during gestation and also in the development and 
maintenance of secondary sex characteristics at puberty. The zona reticularis 
produces the androgenic C19 steroids.
Although numerous steroids have been isolated from adrenal tissue, the only steroids 
normally secreted in physiologically significant amounts are aldosterone, cortisol, 
corticosterone, dehydroepiandrosterone ( DHEA ), and androstenedione. Other 
steroids that are secreted in small amounts are 18-hydroxycorticosterone, 
pregnenolone, progesterone, testosterone, and oestrogens.
Adrenocortical secretion is controlled primarily by adrenocorticotropic hormone ( 
ACTH ) from the anterior pituitary, but mineralocorticoid secretion is also subject to
4control by the renin-angiotensin system. ACTH binds to high affinity receptors on the 
plasma membrane of adrenocortical cells and activates adenylate cyclase. The 
resultant increase in cAMP activates phosphoprotein kinases which in turn increase 
the activity of a number of cell processes. Activated cholesterol esterase produces free 
cholesterol from cholesterol esters stored in the cytoplasm. The free cholesterol is 
transported to the mitochondria where it is converted to the common steroid hormone 
precursor, pregnenolone, at the inner mitochondrial membrane by the action of 
P450scc ( cholesterol 20, 22-desmolase )(Lambeth and Stevens 1985). Continued 
elevation of ACTH increases mRNA transcription and protein translation rates for 
each of the enzymes in the steroidogenic pathway (Boggaram et al. 1985; Voutilainen 
and Miller 1987).
An outline of steroid biosynthesis in the adrenal cortex is given in Figure 2. The 
location of each enzyme in the adrenal cortex is indicated.
G F RP-450.
F RFR_
P-iSO,
DEHYOROEPUNOROSTEHOJC17-OH PREGNENOLONE
FR F R
17-OM PROGESTERONE
GF R
CH-OH
1 1-OEOXYCORTISOLDEOXYCORTICOSTERONE
B g f r
N*/  CH jCH
G F R
O U O H
0= 0
CORTISOLCCRTICOSTEROrC
G F R
C H ,CH
ALDOSTEROfC
Figure 2: Simplified scheme for adrenal steroidogenesis.
The location of each enzyme in the adrenal cortex is indicated. 
G - zona glomerulosa; F - zona fasciculata; R - zona reticularis.
6Testicular steroidogenesis
The testes are the major site of androgen production in the male. Androgens are 
essential for the development and maintenance of the male genitalia and secondary 
sex characteristics.
The testes are made up mainly of loops of convoluted seminiferous tubules, along the 
walls of which spermatozoa are formed from primitive germ cells. Between the 
seminiferous tubules are nests of cells known as Leydig cells which are responsible 
for the bulk of androgen production. Small amounts of androgen are also produced by 
the seminiferous tubules (Bell et al. 1971; Dufau, et al. 1971). As Leydig cells do not 
contain many of the enzymes found in the adrenal cortex e.g. 11- and 21- 
hydroxylases, no glucocorticoids or mineralocorticoids are synthesised.
Although testosterone is the principal androgen secreted by the testes, in many target 
tissues it is converted to the more potent 5 alpha dihydrotestosterone by the enzyme 5 
alpha reductase. In plasma, 97% of testosterone is bound to protein: 40% to sex 
hormone binding globulin ( SHBG), 40% to albumin, and 17% to other proteins (Doe 
and Seal 1963; Burke and Anderson 1972). Only the testosterone which is not bound 
to the SHBG is available for binding to the androgen receptor (Lasnitzki and Franklin 
1972). In addition to testosterone, testosterone precursors such as androstenedione 
and DHEA also enter the circulation. Figure 3 illustrates the biosynthesis of 
testosterone in the testes. There are two major pathways for testosterone biosynthesis: 
the A5 pathway involving the 5-ene-3B-hydroxysteroids pregnenolone, 17 
hydroxypregnenolone and DHEA, and the A4 pathway involving the 4-ene-3- 
oxosteroids, progesterone, 17 hydroxyprogesterone, and 4-androstenedione (Dorfman 
and Ungar 1965). Various workers have attempted to determine the relative 
importance of the A4 and A5 pathways. In rodents the A4 pathway is favoured 
(Shikita et al. 1964; Slaunwhite and Burgett 1965), whereas in humans the A5 
pathway is the most important (Gower and Bicknell 1972). Small amounts of
7oestrogens are also produced by the testes. 70% of oestradiol in the plasma of adult 
men is formed by aromatization of circulating testosterone and androstenedione and 
most of the remaining 30% is secreted directly by the testes (Longcope et al. 1972).
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Figure 3: Biosynthesis and metabolism of testosterone
Although the main secretory product of the Leydig cells is testosterone, 
some of the precursors also enter the circulation.
The production of testosterone is controlled by pituitary luteinising hormone ( LH ). 
LH stimulates the formation of cholesterol from cholesterol esters and the conversion 
of cholesterol to pregnenolone via the activation of protein kinases. Testosterone and 
other androgens exert an inhibitory feedback effect on pituitary LH.
Ovarian steroidogenesis
The ovaries are situated in the pelvis on either side of the uterus. Each ovary is 
attached to the broad ligament of the uterus by a fold of peritoneum. The centre of 
each ovary is known as the medulla or stroma and consists mainly of connective 
tissue containing many collagen fibres. Surrounding the medulla is the cortex which 
consists of a layer of epithelium ( germinal epithelium) and a number of cystic spaces 
of various sizes, the Graafian follicles, each of which contains an immature ovum.
At the start of each menstrual cycle, several of these follicles enlarge, and a cavity 
forms around the ovum. In humans, one of the follicles in one ovary continues to 
develop while the others regress. The structure of the maturing follicle is shown in 
Fig 4. The theca interna and granulosa cells of the follicle are the respective sites of 
progesterone and oestrogen biosynthesis in the ovary. After ovulation the cells of the 
corpus luteum continue to secrete large amounts of progesterone. If pregnancy occurs 
the corpus luteum persists and there are usually no more periods until after delivery. 
If there is no pregnancy the corpus luteum degenerates (Guraya 1971; Fuchs and 
Klopper 1977).
In addition to oestrogens and progesterone, the ovaries also secrete 17- 
hydroxyprogesterone, pregnenolone, 17-hydroxypregnenolone, and a small amount of 
androgens; testosterone, androstenedione, and DHEA. The oestrogens synthesised are 
responsible for the development of the female sex organs and the secondary sex 
characteristics. They are involved in preparing the female reproductive tract in order 
to receive the fertilised ovum. During pregnancy, oestrogens act synergistically with 
the other ovarian hormone progesterone to maintain gestation (Guraya 1971; Fuchs 
and Klopper 1977). They also effect the development of the breasts, the typical 
female body shape, texture of the skin, and hair growth. 176-oestradiol, the major 
secreted oestrogen and the most potent, is in equilibrium in the circulation with 
oestrone. Oestrone is further metabolised to oestriol, the least potent oestrogen,
9mainly in the liver. Approximately 3% of the circulating oestradiol is free and the 
remainder is bound to protein: 60% to albumin and 37% to SHBG (Burke and 
Anderson 1972).
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Figure 4: Ovarian cvcle(Gorbman and Bern 1962)
Diagram of a mammalian ovary, showing the sequential development of a 
follicle, formation of corpus luteum, and, in the centre, follicular atresia. A 
section of the wall of a mature follicle is enlarged at the upper right.
Progesterone is responsible for the progestational changes in the endometrium and the 
cyclic changes in the vagina and cervix. It decreases the number of oestrogen 
receptors in the endometrium and increases the rate of conversion of 176-oestradiol to 
less active oestrogens, in breast it stimulates the development of lobules and alveoli. 
During the luteal phase of the cycle progesterone production by cells of the corpus 
luteum increases approximately 20 fold, mainly via the A4 pathway (Guraya 1971; 
Fuchs and Klopper 1977).
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The granulosa cells of the follicle are the major site of oestrogen production.However 
they can only do so when provided with androgens from the theca interna cells. Theca 
interna cells have many LH receptors, and LH acts via cyclic AMP to increase 
conversion of cholesterol to androstenedione mainly by increasing the flux of A5 
steroids to DHEA. Androstenedione synthesised in the thecal cells is secreted directly 
into the circulation. Some androstenedione also enters adjacent granulosa cells. 
Aromatase, an enzyme expressed in granulosa cells, converts the androstenediol to 
oestradiol ( Fig 5 ). The same enzyme also catalyses the biosynthesis of oestrone by 
aromatization of androstenedione. The oestradiol synthesised by the granulosa cells is 
discharged into the circulation and some is also secreted into the follicular fluid. As 
the granulosa cell layer is relatively avascular it is not clear whether the newly 
synthesised oestrogens pass directly into the circulation or whether they have to pass 
through the theca interna cells to reach the capillary network (Hillier 1991). The 
possibility exists that steroids secreted by the granulosa cells may be altered by the 
thecal cells before they reach the circulation.
Granulosa cells have many follicle stimulating hormone ( FSH ) receptors, and FSH 
facilitates their secretion of 176-oestradiol by acting via cyclic AMP to increase 
aromatase activity in the cells. FSH also induces LH receptors coupled to steroid 
biosynthesis in granulosa cells; aromatase is therefore under direct control of both 
FSH and LH in the preovulatory follicle (Hillier 1991)( Fig 6).
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Figure 5: Biosynthesis and metabolism of oestrogens.
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Figure 6: Regulation of oestrogen biosynthesis in the ovary.
( adapted from Hillier 1991)
Androstenedione synthesised in thecal cells enters the efferent follicular 
vasculator to be secreted as the major follicular androgen. 
Androstenedione also traverses the lamina basalis and enters adjacent 
granulosa cells where it is aromatized to oestradiol. Oestradiol formed 
in granulosa cells is discharged into the ovarian vein.
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Male pseudohermaphroditism ( MPH )
Testosterone and Mullerian regression factor ( MRF), a glycoprotein secreted by the 
Sertoli cells of the testes, are essential in the sexual development of the male fetus. 
MRF acts alone to inhibit the development of the Mullerian ducts; MRF and 
testosterone act together to develop the epididymides, vas deferens, seminal vesicles, 
and ejaculatory ducts from the Wolffian ducts (Jost 1970). Testosterone is also 
required for suppression of the breast anlage (Wilson et al. 1980) and indirectly for 
the normal formation of the male external genitalia.
If the embryonic testes are defective MPH results. A pseudohermaphrodite is an 
individual with the genetic constitution and gonads of one sex and the genitalia of the 
opposite sex. Failure of the testes to produce testosterone and MRF results in genetic 
males with both external and internal female genitalia. However, if the problem is 
limited to a defect in production of testosterone or of 5 alpha dihydrotestosterone ( the 
active form of testosterone in some tissues) then the female genital ducts do not form 
due to the production of MRF. Individuals with this syndrome exhibit micropenis, 
hypospadias, and gynaecomastia (Jost 1970; Wilkins 1975; Wilson et al. 1980).
MPH can result from a deficiency in any one of the enzymes involved in the 
biosynthesis of testosterone and 5 alpha dihydrotestosterone. In other forms of MPH, 
androgen receptors on target tissues may be absent or abnormal. MPH may also occur 
in the presence of normal androgen receptors and testosterone production when there 
are congenital defects in the molecular events that occur after receptor binding 
(Morris 1953; Goldstein and Wilson 1974; Wilson and Goldstein 1975; Griffin and 
Wilson 1980).
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Androgens in the female
The four primary circulating androgenic steroids in women are DHEA, DHEA-S, 
androstenedione and testosterone ( in some tissues testosterone is converted to 5 alpha 
dihydrotestosterone by 5 alpha reductase ). Only testosterone and 5 alpha 
dihydrotestosterone are capable of binding to the intracellular androgen receptor, 
DHEA, DHEA-S and androstenedione do not bind to the androgen receptor and are 
classed as androgen pre-hormones. The androgenic activity of these latter steroids 
depends solely on the extent to which they are converted to testosterone or 5 alpha 
dihydrotestosterone in peripheral tissues.
In normal women, approximately 50-70% of circulating testosterone is derived from 
peripheral conversion of androstenedione (Horton and Tait 1966; Bardin and Lipsett 
1967), the androstenedione being synthesised in the ovary and the adrenals. Direct 
ovarian production of testosterone is estimated to be between 5 and 20% of total 
circulating testosterone. The adrenal contribution is estimated between 0 and 30% 
(Kirschner and Bardin 1972; Moltz et al. 1983). Metabolism of DHEA and A5 
androstenediol accounts for approximately 10-15% of plasma testosterone (Kirschner 
et al. 1973; Clark 1986). In non-pregnant women, 75-80% of circulating testosterone 
is bound to gonadal steroid-binding globulin, 20-25% is loosely bound to albumin 
(Vermuelen et al. 1971) and about 1% circulates freely. Only the testosterone that is 
not bound to SHBG is available for binding to the androgen receptor. SHBG does not 
bind androstenedione, DHEA, or DHEA-S.
The levels of circulating testosterone fluctuates very little in normal women, however 
DHEA, DHEA-S, and androstenedione levels demonstrate significant diurnal 
fluctuations. Circulating DHEA and DHEA-S are almost exclusively of adrenal origin 
( 80% and 90% respectively )(Horton and Tait 1966). By contrast, during the 
follicular phase of the menstrual cycle, androstenedione production is evenly divided
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between the ovary and the adrenals. At midcycle, however, the ovarian contribution 
increases to two thirds of the total (Abraham 1974).
Neither ovarian nor adrenal androgen secretion in women is directly regulated. 
Although LH and ACTH do stimulate adrenal and ovarian androgen secretion 
respectively, the secreted androgens do not feed back in an autoregulatory manner at 
the level of the hypothalamus-pituitary (Kirschner and Bardin 1972).
The physiological role of androgens in men is well defined, however, in the female 
the physiological significance of androgens is largely unknown. Androgens are 
known to serve as oestrogen precursors and may be involved in the regulation of 
ovarian function at gonadal level. Growth and development of pubic and axillary hair 
are also androgen dependent. An excess of androgen production during gestation 
results in female pseudohermaphroditism. Individuals with this syndrome have 
normal internal female genitalia, however varying degrees of labial fusion and 
clitoromegaly occur depending on the levels of androgen and the duration of 
exposure during gestation. In prepuberal and adult females an excess of androgen 
production leads to the adrenogenital syndrome. Symptoms include clitoromegaly , 
oligomenorrhea or amenorrhea, hirsutism, obesity, acne, male muscle mass, and in 
some cases polycystic ovaries. Excessive androgen production in females is 
commonly the result of congenital enzyme deficiencies in 21-hydroxylase, 118- 
hydroxylase, or 38-hydroxysteroid dehydrogenase. Excess androgens can also occur 
as a result of Cushings disease, where excess ACTH secretion results in stimulation 
of adrenal androgen production in addition to hypercortisolism. Less commonly, 
excess levels of androgen can occur as a result of virilizing tumours of the ovary or 
adrenal.
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Congenital adrenal hyperplasia ( CAH)
CAH affects about 1 in 5000 births. It results from a deficiency in one or another of 
the enzymes involved in cortisol biosynthesis. Deficient cortisol synthesis leads to a 
rise in ACTH production which in turn leads to hyperplasia of the adrenal cortex. The 
degree of hyperplasia depends on the extent to which enzyme activity is reduced.
The initial diagnosis of CAH is based on clinical symptoms and both serum and 
urinary steroid analysis. Enzyme assays can only be carried out either post-mortem in 
severe cases or occasionally when tissue is removed therapeutically in some milder 
cases. Steroid analysis can be enhanced by the use of synacthen ( synthetic ACTH ). 
Artificial stimulation of the cortisol biosynthetic pathway by synacthen leads to an 
overproduction and accumulation of cortisol precursors proximal to the block. Each 
enzyme deficiency produces characteristically abnormal levels of adrenal hormones 
and precursors (Finkelstein and Schaeffer 1979). Defects in the following enzymes 
have been associated with CAH ( Table 1 ). Only 21, 116, and 36 deficiencies are 
associated with virilisation.
Table 1
Deficiency Enzyme Frequency
Cholesterol desmolase P450scc Rare
36-hydroxysteroid
dehydrogenase
36-hydroxysteroid
dehydrogenase
Frequent?
17alpha-hydroxy lase P450cl7 Rare
17,20-lyase P450cl7 Rare
21-hydroxylase P450c21 1:12,000
11-hydroxylase P450cll 1:100,000
Corticosterone methyl 
oxidase type II
P450cll Rare
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21-hvdroxvlase deficiency
This enzyme deficiency is the most common cause of CAH accounting for >90% of 
all cases. 21-hydroxylase converts progesterone to 11-deoxycorticosterone, and 17- 
hydroxyprogesterone to 11-deoxycortisol. Deficiency in 21-hydroxylase is generally 
characterised by raised levels of 17-hydroxyprogesterone in blood and large quantities 
of metabolites such as pregnenetriol and 17-hydroxypregnenolone in the urine. As 17- 
hydroxyprogesterone is a precursor of androstenedione and testosterone, the secretion 
of both of these androgens is also increased. Excessive androgen production results in 
virilisation of both males and females. In female newborns, the external genitalia are 
masculinized; gonads and internal genitalia are normal. If untreated postnatally, both 
males and females may manifest rapid growth, penile or clitoral enlargement, 
precocious adrenarche, and ultimately early epiphyseal closure and short stature.
There are four recognised clinical forms of 21-hydroxylase deficiency: salt losing, 
simple virilising, late onset ( non-classical), and cryptic, all of which are inherited in 
an autosomal recessive manner. The salt wasting form accounts for approximately 
half of the reported cases. Inadequate production of salt retaining steroids, especially 
aldosterone, in the zona glomerulosa results in the inability to retain urinary sodium. 
Loss of sodium can result in shock or death during the neonatal period. The simple 
virilising form is due to an isolated defect in the cortisol pathway i.e. only the enzyme 
activity in the zona fasciculala-zona reticularis is affected. Aldosterone synthesis and 
conservation of urinary sodium are normal. The cryptic and late-onset forms of 21- 
hydroxylase deficiency are relatively mild in comparison to the classical forms. 
Usually patients exhibit a mild deficiency in cortisol synthesis and either remain 
asymptomatic ( cryptic form ) or become virilised in late childhood or at puberty ( 
late-onset form )(New, White et al. 1989).
There are two genes encoding 21-hydroxylase, CYP21A and CYP21B, both of which 
are closely linked to the HLA major histocompatibility complex on the short arm of
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chromosome 6 (White et al. 1983; Carrol et al. 1985; White et al. 1985). In addition 
there are specific associations between HLA haplotypes and different forms of 21- 
hydroxylase deficiency (O'Neill, et al. 1982). DNA sequence analysis has confirmed 
that the CYP21B gene encodes 21-hydroxylase, whereas the CYP21A gene is a 
pseudogene. Analysis of the 21-hydroxylase genes in deficient families has revealed a 
variety of gene defects including point mutations, gene deletions, gene conversions, 
and unequal crossovers of genetic material between the inactive gene A and the active 
gene B (Raum et al. 1984; Carrol et al. 1985; Donohoue et al. 1986; Werkmeister et 
al. 1986; Globerman et al. 1987; Amor et al. 1988; White et al. 1988). It has been 
suggested that 21-hydroxylase contains two active sites: one active on progesterone 
and the other specific for 17 alpha hydroxyprogesterone. In the salt losing variety 
both sites are defective and in the simple virilizing form only the second site is 
defective (Orta-Flores et al. 1976). This hypothesis may be investigated in the future 
by site directed mutagenesis of the CYP21B gene.
1 lB-hvdroxvlase deficiency
This enzyme deficiency accounts for approximately 5-8% of reported cases of CAH 
(Wilkins 1965; Bongiovanni 1978; Werder et al. 1980). The deficiency results in 
elevated levels of 11-deoxycortisol ( compound S ) and deoxycorticosterone ( DOC ) 
in the serum. An elevation of the corresponding tetrahydro metabolites, tetrahydro- 
11-deoxycortisol ( THS ) and tetrahydrodeoxycorticosterone ( THDOC ) can be 
observed in urine (Eberlain and Bongiovanni 1956). The cortisol precursors that 
accumulate proximal to the block are shunted into the androgen biosynthetic pathway. 
Excessive foetal androgen production in females results in ambiguous genitalia with 
normal internal female reproductive organs. In both males and females, penile and 
clitoral enlargement, precocious adrenarche, and early epiphyseal closure can result if 
untreated. Mild, late-onset, and even cryptic forms of 116-hydroxylase deficiency 
have also been reported (Gabrilove et al. 1965; Newmark et al. 1977; Cathelineau et
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al. 1980; Birmbaum and Rose 1984; Rosier and Leibermann 1984; Hurwitz et al.
1985). In many cases of 116-hydroxylase deficiency, hypokalaemia and hypertension 
are thought to be caused by increased levels of DOC and other precursors in the 
mineralocorticoid pathway but this is not certain.
Initial work by Hall et al ( 1985 ) indicated that the enzymatic activities of 116- 
hydroxylase and corticosterone methyl oxidase type I ( CMOI:18 hydroxylase ) and 
type II ( CMOII:18 dehydrogenase )(Yanagibashi et al. 1986) resided in the one 
protein. Further work has shown that two distinct proteins exist (Chua 1987) and the 
cDNAs encoding for two putative human cyt P-450i 16/18 genes have recently been 
cloned. The two genes CYP11B1 and CYP11B2, which are 95% identical, have been 
assigned to chromosome 8q22. The physical distance between these genes is not yet 
known, however, they are closely linked and thought to lie in tandem on chromosome 
8q22, CYP11B1 upstream of CYP11B2 (Mornet et al. 1989). It is thought that 
CYP11B1 encodes cyt P-450iib ( 116-hydroxylase ) and CYP11B2 encodes a 
seperate enzyme cyt P-450 aldosterone synthase. A variety of mutations have been 
found in both CYP11B1 and CYP11B2 (White et al. 1991; Yanase et al. 1991; 
Helmberg et al. 1992; Pascoe et al. 1992).
A chimaeric 116-hydroxylase / aldosterone synthase gene has recently been identified 
in a family characterised by glucocorticoid - remediable aldosteronism and 
hypertension. A non-homologous crossover fusing the 5' regulatory region of 116- 
hydroxylase ( expressed in both adrenal fasciculata and glomerulosa ) to the coding 
sequences of aldosterone synthase ( expressed only in adrenal glomerulosa ) is 
thought to be responsible for the physiological abnormalities observed in this family 
(Lifton et al. 1992).
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17 alpha hvdroxvlase deficiency
17 alpha hydroxylase deficiency is a rare defect in which the conversion of 
pregnenolone and progesterone to 17-hydroxypregnenolone and 17- 
hydroxyprogesterone is reduced. Consequently the production of glucocorticoids and 
sex steroids is reduced, and plasma levels of mineralocorticoids, especially 
corticosterone, are increased.
Affected females present as sexually infantile phenotypic females; males exhibit 
pseudohermaphroditism including incomplete Wolffian duct development ( Mullerian 
structures are absent due to normal testicular production of MRF ), and 
gynaecomastia. Both males and females exhibit low renin hypertension and 
hyperkalaemia which is probably due to elevated levels of mineralocorticoids 
(Grumbach and Conte 1985). 17,20-lyase activity resides in the same protein as 17 
alpha hydroxylase (Kominami et al. 1982). Deficiency of 17,20-lyase causes an 
isolated defect in the synthesis of the sex steroids (Zachmann et al. 1972).
It is probable that at least four allelic variants of 17 alpha hydroxylase deficiency may 
exist. Bigliere et al ( 1966 ) reported males and females with complete absence of 
enzyme activity. New et al ( 1970 ) and Jones et al ( 1982 ) reported an incomplete 
block in 17 alpha hydroxylase-lyase activity, and cases of 17 alpha hydroxylase 
deficiency with intact 17,20-lyase activity have also been reported (Bradshaw, et al. 
1987).
The 17 alpha hydroxylase/17,20-lyase protein is encoded by a single gene which has 
been localised to chromosome 10. To date a variety of point mutations, duplications, 
and deletions have been found in cases of combined 17 alpha hydroxylase/17,20- 
lyase deficiency (Kagimoto et al. 1988). Mutations which affect only one function of 
the protein have yet to be found.
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Cholesterol desmolase deficiency
Cholesterol desmolase deficiency is an extremely rare defect also known as lipoid 
adrenal hyperplasia or Prader's syndrome (Prader and Gurtner 1955; Prader and 
Siebenman 1957). The affected patients have severely impaired synthesis of all 
steroids characterised by gonadal hypogenesis or agenesis, severe fluid and 
electrolyte disturbances, and Addisonian pigmentation. In most cases, death occurs 
during infancy due to an acute salt losing crisis.
The gene that encodes P-450scc has been allocated to chromosome 15 (Chung et al.
1986). As yet no gross deletions or rearrangements of the gene have been reported, 
and linkage of the disease to polymorphisms of this gene remains to be demonstrated.
3fi-hvdroxvsteroid dehydrogenase ( 36-HSD ) deficiency
36-HSD catalyses a series of obligatory biosynthetic steps in the synthesis of 
mineralocorticoids, glucocorticoids, and sex steroids. 36-HSD is expressed in adrenal, 
ovary, testes, placenta, and possibly skin sebaceous glands and hair follicles (Luu-The 
et al. 1989; Lorence et al. 1990a). Specifically it converts the A5 36-hydroxysteroids 
pregnenolone, 17-hydroxypregnenolone, DHEA, and androstene 36, 17 diol into the 
respective A4 3-ketosteroids; progesterone, 17 alpha hydroxyprogesterone, 
androstenedione, and testosterone (Bongiovanni and Kellenbenz 1962; Miller 1988; 
Thomas et al. 1989). The conversion involves oxidation of the steroid A ring at the 
C3 position accompanied by a shift of the C-5,6 double bond on the steroid B ring to 
C4,5 on the A ring. A single protein catalyses both steps (Lachance et al. 1990; 
Lorepce et al. 1990a).
36-HSD deficiency results in a high ratio of A5 to A4 steroids, characterised 
specifically by elevated serum levels of the A5 steroids, pregnenolone, 17- 
hydroxypregnenolone, and DHEA, and increased excretion of the A5 metabolites
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pregnenetriol and 16-pregnenetriol in the urine. Baseline serum hormonal 
concentration measurements are insufficient for diagnosis of 36-HSD deficiency, 
instead, ACTH stimulation or the use of urinary 24 hour hormonal concentrations is 
required.
Evidence based on the assay of steroid hormones and their precursors indicates that 
there are a variety of inherited deficiencies of 36-HSD including salt wasting, non-salt 
wasting, classical, and late-onset. The classical form of 36-HSD deficiency is usually 
associated with salt wasting caused by insufficient mineralocorticoid production 
though in some cases the ability to conserve sodium has been intact. In males, 
defective testosterone biosynthesis results in pseudohermaphroditism including 
micropenis, hypospadias, and in later life, gynaecomastia (Bongiovanni and 
Kellenbenz 1962; Mendonca et al. 1987). In contrast, affected newborn females 
exhibit normal sexual differentiation or partial virilisation including clitoral 
enlargement and variable degrees of labial fusion. In later life, females exhibit 
hirsutism, primary or secondary amenorrhea, or irregular menses (Pang et al. 1985). 
The virilisation in females is a result of high levels of circulating DHEA which is 
almost exclusively adrenal in origin. It is likely that conversion of DHEA to potent 
androgens such as testosterone and 5 alpha dihydrotestosterone takes place in 
peripheral tissues such as skin sebaceous glands and hair follicles.
In the past decade there has been an increase in the number of reports of non-classical 
( late-onset ) deficiencies of 36-HSD which are not associated with aldosterone 
synthesis or salt wasting. Children with non-classical 36-HSD deficiency may exhibit 
early appearance of pubic and axillary hair and accelerated growth (Temeck et al. 
1987; Oberfield and Levine 1988). Adult females may exhibit hirsutism, acne, 
temporal balding, irregular menses, and infertility (Axelrod et al. 1965; Lobo and 
Goebelsmann 1981; Bongiovanni 1983; Pang et al. 1985; Bongiovanni 1987;
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Redmond et al. 1988; Schram and Zerah 1990). Little is known about non-classical 
36-HSD deficiency in adult men.
Molecular biology of 36-HSD
Following purification of human placental 36-HSD and the development of 
antibodies in rabbits (Luu-The et al. 1988; Luu-The et al. 1990), the cDNA encoding 
36-HSD type I (Luu-The et al. 1989; Lorence et al. 1990a) and its corresponding gene 
(Lachance et al. 1990; Lorence et al. 1990b) were isolated by the Medical Research 
Council Group in Molecular Endocrinology ( C.H.U.L. Research Centre and Laval 
University, Quebec ). A full length cDNA encoding 36-HSD type I was also cloned 
by Nickson et al ( 1990 )( Glasgow University ) as part of a project sponsored by the 
W.H.O. Task Force on Vaccines for Fertility Regulation. This project involved the 
isolation and eukaryotic expression of cDNAs for placental specific surface proteins 
from a lambda g tll placental library using monoclonal antibodies raised against 
placental trophoblast (Mueller et al. 1987). More recently, the cDNA encoding 36- 
HSD type II (Rheaume et al. 1991) and its corresponding gene (Lachance et al. 1991) 
were isolated by the Quebec group. To date, only two human genes encoding 36-HSD 
have been isolated, however, in rodents at least three genes for 36-HSD have been 
found to be expressed (Zhao et al. 1990; Bain et al. 1991; Zhao et al. 1991) and when 
analysed on southern blots, human DNA shows evidence of six or more sequences 
with homology to 36-HSD probes ( Fig 13 and Lachance et al 1990 ). Ribonuclease 
protection assays have shown 36-HSD type I expression principally in the placenta 
and skin, and 36-HSD type II expression in adrenals, ovary, and testis (Rheaume et al. 
1991).
36-HSD type I ( Fig 7 ) contains a 5' untranslated exon of 53bp and three successive 
translated exons of 232, 165, and 1218bp, respectively, separated by introns of 129, 
3883, and 2162bp. A putative TATA box ( ATAAA ) is situated 28 nucleotides
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upstream from the transcription start site and a putative CAAT box is located 57 
nucleotides upstream from the TATA box (Lachance et al. 1990; Lorence, et al. 
1990b).
The type II gene ( Fig 7 ) contains four exons of 57, 231, 165, and 1214 bp, 
respectively, separated by introns of 128, 3383, and 2162 bp. Two putative TATA 
boxes are situated 28 and 140 nucleotides upstream from the transcription start site 
and two putative CAAT boxes are located 57 and 38 nucleotides upstream from the 
TATA boxes respectively. The nucleotide sequence of the exons of the type II 36- 
HSD gene shows 77.4, 91.8, 94, and 91% similarity with the corresponding exons of 
the type I gene and 84, 83.1, and 73.9% similarity for the introns (Lachance et al. 
1991).
Ikb
TYPE I 
EXONS
1. 53 bp
2. 232 bp
3. 165 bp
4. 1218 bp
INTRONS
A. 129 bp
B. 3883 bp
C. 2162 bp
TYPE n  
EXONS
1. 57 bp
2. 231 bp 
3.165 bp 
4.1214 bp
INTRONS
A. 128 bp
B. 3383 bp
C. 2162
CHROMOSOMAL LOCATION lpl3.1
Figure 7: Gene structure of 36-HSD type I and type n.
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The 38-HSD type I gene encodes a single 42 kDa protein composed of 372 amino 
acid residues (Luu-The et al. 1989; Lorence et al. 1990a). The type II gene encodes a 
41.921 kDa protein of 371 residues (Rheaume et al. 1991). When compared, the two 
protein sequences show 93.5% homology. Both the type I and type II genes contain a 
putative nucleotide cofactor binding site of the B-&-B motif at residues Ser5>Asp36 
and Ser4>Asp35 respectively. The central portion of this 36-HSD sequence is 
GXGGXXG ( residues 10-16 type I, residues 9-15 type I I ), which resembles the 
consensus GXGXXG (Wierenga et al. 1986).
Though the enzymes are both capable of converting the same A5 substrates they differ 
in their kinetics in detail. The type I 38-HSD protein possesses a significantly higher 
affinity ( approximately 5 fold greater ) for pregnenolone, DHEA, and 
dihydrotestosterone than the type II protein. The type I 38-HSD protein possesses 
equivalent affinity for C21 ( pregnenolone ) and C l9 ( DHEA and 
dihydrotestosterone ) steroids, and this is also true for the 38-HSD type II protein 
(Lorence et al. 1990a; Rheaume et al. 1991). Like most steroidogenic enzymes, 36- 
HSD types I and II may be able to catalyse many steps other than their principle 
action in the pathway in which they reside. Though it has been shown that the 38- 
HSD type I and type II proteins have similar substrate specificity for their principle 
substrates, significant differences may exist in their affinities for less common 
substrates.
The 38-HSD type I gene was assigned to chromosome lpl3.1 by Berube et al. (1989 
) and Morrison et al. ( 1990 ). No evidence was produced to suggest the presence of 
38-HSD homologues elsewhere in the genome. The chromosomal location of 38-HSD 
type II has not yet been determined though it is likely that it also is situated on 
chromosome lpl3.1.1 will present evidence which suggests close linkage of the 38- 
HSD type I and type II genes on chromosome 1.
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The central role of the adrenals and gonads in steroid biosynthesis leads to the 
expectation that mutations in the gene for 36-HSD type II will be responsible for most 
of the inherited syndromes of 36-HSD deficiency. Indeed, stop codons and another 
mutation in 36-HSD type II have recently been reported in patients with severe CAH 
due to 36-HSD deficiency (Rheaume et al. 1992). These patients have profound 
deficiencies in the synthesis of mineralocorticoids and glucocorticoids and males are 
affected with pseudohermaphroditism due to a lack of testosterone. This severe 
autosomal recessive condition is now best understood as a failure to synthesize 
steroid precursors in the adrenals and gonads (Rheaume et al. 1992). The three 
families ( Ran, Sta, and Pfe) to be presented in this thesis are affected by a less severe 
form of the deficiency. In each family the deficiency is limited to the production of 
the sex steroids. With the possible exception of family Sta, glucocorticoid and 
mineralocorticoid synthesis remains normal.
Detection of mutations
A variety of methods now exist for the detection of new mutations. Methods such as 
denaturing gradient gel electrophoresis ( DGGE )(Myers et al. 1987), temperature 
gradient gel electrophoresis ( TGGE )(DIAGEN GmbH), single strand conformation 
polymorphism ( SSCP )(Orita et al. 1989), hydrolink gels (Keen et al. 1991), RNase 
A cleavage (Myers et al. 1985), and chemical cleavage (Cotton et al. 1989) provide 
screening systems that allow a mutation to be located to an exon of a specific gene, or 
even to a specific isoform of a gene family, and so focus the requirement for direct 
sequencing. The ready detection of homozygotes and heterozygotes allows rapid tests 
of the genetic co-segregation of the disease and the putative underlying mutation. 
DGGE has proved a powerful tool in this respect and several methodological aspects 
have been encountered in this study. Denaturing gradient gel electrophoresis allows 
the separation of DNA molecules which differ by as little as a single base 
substitution. The method involves the electrophoresis of double stranded DNA
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fragments through a standard acrylamide gel containing a linear gradient, increasing 
from top to bottom, of DNA denaturants, such as urea and formamide. The increasing 
concentration of denaturants in the gel is equivalent to a proportional increase in 
temperature. DNA molecules differing by as little as one base pair will have a slightly 
different melting temperature and will be separated on the gel. A full description of 
DGGE is given by Myers et al ( 1987 ).
The DGGE method does require to be tuned for specific gene segments, and 
mutations that can barely be distinguished from controls can often be convincingly 
and reproducibly resolved by small changes in DGGE conditions. Some important 
factors to be taken into account when running DGGE are (1) the % denaturant to use 
(2) the size of pores in the gel i.e. the acrylamide concentration (3) the length of run 
(4) the voltage to use. The MELT programmes of Lerman and Silverstein ( 1987 ) 
were used to optimise DGGE for the screening of each exon of 36 HSD types I and II. 
The computer readouts were open to interpretation and were therefore only treated as 
a rough guide. As suggested by Lerman, different gradients and run times were 
attempted for each fragment of DNA.
I have used DGGE to analyse the coding sequence of the 36-HSD type I and type II 
genes in each of the affected patients. In addition, automated sequencing of PCR 
products was used to screen the coding sequence of 36-HSD type II. Initially, only the 
affected patients were available for analysis. The collection of samples from other 
family members frequently proved difficult and time consuming as some came from 
outside Scotland. For this reason, some results are not presented in chronological 
order.
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MATERIALS AND METHODS
Steroid assays: Serum steroids were measured by standard radioimmunoassay 
procedures (Forest et al. 1980). Urinary steroid profile analysis was performed by 
capillary column chromatography of steroid methyloxime-trimethylsilyl ether derivatives 
by a method similar to that developed by Shackleton and Honour (1976).
Isolation of genomic DNA: 10ml of peripheral blood was mixed with 75ml of 0.32M 
sucrose, lOmM Tris-HCl (pH 7.5), 5mM MgCl, and 1% Triton X-100 at 4°C. White cells 
were collected by centrifugation at 10,000 rpm for 10 minutes at 4°C. White cells were 
resuspended in 4.5ml of 0.075M NaCl, 0.024M EDTA using a pasteur pipette. SDS and 
proteinase K were added to a final concentration of 0.1% and 200ug/ml, respectively, and 
the suspensions were incubated at 37°C overnight. DNA was extracted by 
phenol/chloroform, and precipitated by adding 0.5ml 3M Sodium acetate and 11ml 
ethanol (100%). DNA was dissolved slowly over 2 days at 4°C in 1ml TE buffer (lOmM 
Tris pH 7.6, ImM EDTA). A 1 in 50 dilution of the sample was examined 
spectrophotometrically at 260nm and 280nm to determine the quality and purity of the 
DNA.
Agarose gel electrophoresis: Unless otherwise indicated, all agarose gels were run in 
TBE buffer ( 89mM Tris, 89mM boric acid, 2mM EDTA). Ethidium bromide was added 
to each gel at a concentration of 0.5ug/ml. The sample loading buffer used consisted of 
0.25% bromophenol blue, 40% ( w/v ) sucrose in water ( 6x buffer).
Southern blot analysis: Human genomic DNA was isolated from peripheral blood as 
described. 5ug of genomic DNA was digested with EcoRI and Xbal restriction 
endonucleases. Each reaction mixture ( final volume 30ul) consisted of 5ug human 
genomic DNA, EcoRI reaction buffer ( 5mM Tris ( pH8.0 ), ImM MgCl2, lOmM NaCl) 
or Xbal reaction buffer ( 5mM Tris ( pH8.0), ImM MgCl2,5mM NaCl), spermidine
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lOOmM, and 30 units of enzyme. The reaction mixture was incubated at 37°C overnight. 
The DNA was electrophoresed through a 0.8% agarose gel at 3V/cm of gel length 
overnight. Hindlll/EcoRI-digested lambda DNA fragments were used as molecular size 
markers. The DNA was transferred to nylon membranes ( PALL) as described (Southern 
1975). Filters were prehybridised for 4 hours at 65°C in 6xSSC, 5xDenhardts, 0.5% SDS, 
and lOOug/ml denatured herring sperm DNA. The filters were then probed with 36-HSD 
type I exon specific DNA ( Fig 12). Probes 1/2, 3, and 4 were amplified from human 
genomic DNA by PCR using primers a&b, c&d, and e&h ( Fig 23 ), respectively, under 
the conditions specified in Table 8. PCR products were electrophoresed through a 1% 
agarose gel at 8V/cm gel length for 1-2 hours. Bands were visualised using long 
wavelength ultraviolet light and relevant bands were excised using a scalpel. DNA was 
purified from the gel slice using a Magic Prep column ( Promega). The probes were 
labelled with [alpha-32P]dCTP ( 3000Ci/mmol; Amersham) by the random primer 
method to a specific activity of 109dpm/ug. Probes were heated at 100°C for 2 minutes. 
5xl06dpm of probe was added to 10ml of fresh prehybridisation buffer. The filters were 
hybridised at 65°C overnight. The filters were washed twice (15 minutes each ) in 2xSSC 
with 0.5% SDS at 22°C and twice (60 minutes each ) at 65°C in 2xSSC with 0.5% SDS. 
Autoradiography was performed at room temperature using Kodak X-omat S films for 2 
days.
Random priming of DNA: 20ng of DNA was labelled with [alpha-32P]dCTP ( 
3000Ci/mmol; Amersham) by the random primer method, using a Ready-To-Go DNA 
labelling kit ( Pharmacia), to a specific activity of 109dpm/ug. The reaction mixture ( 
final volume 50ul) consisted of 20ng DNA in 45ul water, 5ul [alpha-32P]dCTP ( 
lOuCi/ul), and Reaction Mix ( dATP, dGTP, d lT’P, FPLC pureR Klenow fragment ( 4-8 
units )) , and random oligodeoxyribonucleotides, primarily 9-mers.). DNA was heated at 
100°C for 2 minutes before adding to the above mix. The reaction was incubated at room 
temperature overnight then the reaction was stopped using 2ul of 0.5M EDTA. After 
adjusting the volume to lOOul with TE the labelled DNA was separated from the
unincorporated [alpha-32P]dCTP by chromatography on a Sephadex G-50 column, using 
a 2cm x 1cm bed ( height x diameter).
Polymerase chain reaction (PCR): Segments of the genes for 36-HSD types I and n  
were amplified from lymphocyte DNA by PCR. PCRs were performed in a Hybaid 
"Omnigene" for 40 cycles of: [1] 91°C for 30sec, [2] annealing temperature for 30sec, [3] 
72°C for 30sec. A final cycle of 95°C for 10 minutes was included to aid the formation of 
heteroduplexes. The annealing temperature of each pair of primers is shown in Table 8. (p 
The reaction mixture ( final volume 50ul) consisted of amplification buffer ( 50mM KC1, 
lOmM Tris-HCl ( pH9.0), 0.1% Triton X-100,15mM MgCl), 0.2mM of each dNTP, 
luM of each oligonucleotide primer, 0.5-1 unit of Taq DNA polymerase (Promega), and 
10-50ng of DNA template.
BgHI RFLP in 36-HSD type I exon 4: The PCR amplified product of 36-HSD type I 
exon 4 was precipitated and then digested with 10 units of BglH (Promega) at 37°C for 2 
hours. The restriction fragments were then separated on a 1% agarose gel at 8V/cm gel 
length for 1-2 hours, or analysed by DGGE for haplotype analysis.
Denaturing gradient gel electrophoresis: The DGGE system including materials, 
reagents, gel preparation, and electrophoresis has been described in detail by Myers et 
al ( 1987 ). Segments of the genes for 38-HSD types I and II were amplified from 
lymphocyte DNA by PCR, using the primers, GC clamps and conditions shown in 
Table 8. In each case the sequence of the GC clamp at the 5' end of the PCR primer 
was that defined by Sheffield et al (1989). PCR fragments, with GC clamps in either 
orientation, were screened for mutations using DGGE. DGGE was carried out in 
6.5% polyacrylamide gels ( 37.5:1, acrylamide:bis acrylamide ) in a buffer tank 
containing 9 1 of TAE buffer (40mM Tris, 20mM sodium acetate, ImM EDTA, pH 
7.4) ( Fig 8 ). Denaturing gradient gels (16 x 18 x 0.1 cm) were poured using a Dual 
Slab Electrophoresis SE 600 gel former ( Hoeffer). A Grant Immersion Thermostat (
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TA 0-150 ) was used to circulate the electrophoresis buffer at a constant temperature 
of 60°C. The power pack used was a Kikusui PAB ( 250-0.25 ). It was necessary to 
remove the small metal bar connecting the positive and negative electrodes before 
using for DGGE. Failure to do so resulted in a loss of current. Appropriate denaturant 
and acrylamide concentrations were achieved in each gel by the mixing of two stock 
solutions, 0% denaturant stock ( 6.5% acrylamide ( 37.5:1, acrylamide:bis acrylamide 
) in TAE ), and 100% denaturant stock ( 6.5% acrylamide ( 37.5:1, acrylamide:bis 
acrylamide ), 7M urea, 40% formamide in TAE ). Stock solutions were filtered twice 
through Whatman No. 1 paper and stored in brown bottles at 4°C. 1/200 gel volume of 
20% ammonium persulphate and 1/2000 gel volume of TEMED ( N, N, N', N'- Tetra 
methyl ethylenediamine ) were used as polymerisation catalysts. Approximate 
denaturant gradients, electrophoresis voltages and times were selected for each 
amplified segment of genomic DNA with the aid of the MELT programme ( Lerman 
and Silverstein 1987 ) and were refined by trial and error. The conditions for best 
resolution of each gene segment are shown in Table 8. All DGGE gels were run at 
80V, 100mA for 20 hours. Best resolution was achieved in the centre and lower two 
thirds of the gel matrix. Parameters including the concentration of acrylamide and 
denaturants in the DGGE gel and the voltage and duration of electrophoresis were 
varied to allow the DNA sample to resolve at approximately half way down the gel. 
DGGE gels were stained by immersion in 280 ug/ul ethidium bromide for 30 minutes.
Samples which exhibited altered mobility on DGGE were originally analysed by 
excising the band of interest from the gel, reamplifying the DNA fragment, then 
sequencing the resulting PCR product directly. This method was rendered obsolete by 
the advent of PCR cloning vector technology.
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60 C
Upper buffer chamber
Thermostat/Pump
Lower buffer chamber
Denaturing gel
Figure 8: Denaturing gradient gel electrophoresis
Figure 8 illustrates the equipment used in the running of denaturant
gradient gels. The direction of buffer flow is indicated by arrows.
Isolation of DNA fragments from DGGE gels: DGGE gels were examined under 
long wavelength ultraviolet light and bands of interest were excised using a scalpel. A 
fresh scalpel blade was used for each band. The gel slice was transferred to a 
microfuge tube and crushed against the wall of the tube using a disposable pipette tip. 
200ul of elution buffer ( 0.5M ammonium acetate, lOmM magnesium acetate, ImM 
EDTA ( pH 8.0 ), 0.1% SDS ) was added to the tube. The sample was incubated at 
37°C on a rotating wheel for 12-16 hours. The sample was centrifuged at 12,000g for 
1 minute and the supernatant transferred to a fresh microfuge tube. The DNA was 
precipitated then resuspended in lOOul water. lOul was used as template for PCR 
amplification of the fragment. PCR products were run on suitable denaturing gels 
alongside controls ( the original PCR product ) to confirm successful isolation and 
reamplification.
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Direct sequencing of PCR products: PCR products were electrophoresed through a 
1% agarose gel at 8V/cm gel length for 1-2 hours. Bands were visualised using long 
wavelength ultraviolet light and relevant bands were excised using a scalpel. DNA 
was purified from the gel slice using a Magic Prep column ( Promega ). Sequencing 
was carried out using the sequenase version 2.0 DNA sequencing kit ( U.S.B.) or by 
cycle sequencing using an Applied Biosystems automatic sequencer.
pT7 Blue T-vector cloning of PCR products: 50ng ( 0.03pmol) of pT7 Blue T- 
vector was ligated with 10-50ng ( 0.04-0.2pmol) of PCR product. PCR products were 
not band purified before cloning into pT7 Blue T-vector. The reaction mixture ( final 
volume lOul) consisted of T4 DNA ligase buffer ( 30mM Tris-HCl ( pH7.8 ), lOmM 
MgCl2 lOmM DTT ), lOmM ATP, 50ng pT7 Blue T-vector, 10-50ng PCR product, 
and 2-3 Weiss units T4 DNA ligase ( B.R.L.). The reaction mixture was incubated at 
15°C overnight, lul of ligation reaction was added to 20ul of Nova Blue competent 
cells ( Invitrogen ) and placed on ice for 30 minutes. The cells were heated for 40 
seconds in a 42°C water bath and then placed on ice for 2 minutes. 80ul of SOC 
medium ( 20g bacto-tryptone, 5g bacto-yeast extract, 0.5g NaCl, 20ml of 1M glucose, 
950ml H2O) was added and the cells incubated at 37°C for 1 hour. 300ul more SOC 
medium was added and lOOul portions were spread on LB ( Luria-Bertani ) agar 
plates ( lOg bacto-tryptone, 5g bacto-yeast extract, lOg NaCl, 15g bacto-agar, 950ml 
H2O ) containing 50ug/ml ampicillin plus 15ug/ml tetracycline. For blue/white 
screening of recombinants 35ul of 50mg/ml X-gal in dimethylformamide and 20ul 
lOOmM IPTG in water were spread on the plates and allowed to soak in for about 30 
minutes prior to plating. Plates were incubated at 37°C overnight. Putative clones 
were identified by blue/white selection.
Confirmation of putative clones by PCR: Individual white colonies were selected 
and grown up in 2ml LB broth ( lOg bacto-tryptone, 5g bacto-yeast extract, lOg NaCl, 
950ml H2O ) incubated at 37°C overnight. lOul of culture was added to 40ul water
34
and heated in a boiling water bath for 5 minutes. lOul of the boiled culture was used 
as template in the appropriate PCR reaction ( Table 8 ). PCR products were screened 
for artefactual PCR mutations by resolution on the appropriate DGGE gel alongside 
controls ( the original PCR product ). Only independent clones which resolved 
indistinguishably from the original genomic template were selected for sequencing. 
Large scale plasmid preparation of DNA for sequencing was performed using Qiagen 
columns. Sequencing was carried out using the sequenase version 2.0 DNA 
sequencing kit ( U.S.B.).
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RESULTS 
Patient profiles
The following families were selected for analysis on the basis of clinical and 
biochemical data suggestive of 36-HSD deficiency.
Family Sta (Fisher et al. 1988)( Fig 9)
Sta III-l presented at birth with normal testes and perineal hypospadias. From early 
childhood onwards, several episodes of hyponatraemia were diagnosed. Urinary 
steroid analysis showed high basal levels of pregnenolone, 16 alpha 
hydroxypregnenolone and 16 alpha hydroxy DHEA with normal cortisol metabolites, 
establishing the diagnosis of partial 36-HSD deficiency ( Table 2 ). The raised basal 
plasma renin activity ( PRA ) suggested a mild salt loss. The fall in urine sodium 
while on a low sodium diet was surprising since plasma aldosterone levels declined. 
Fisher suggests that the presence of a dexamethasone suppressible aldosterone 
antagonist may be responsible.
Sta III-2 presented at birth with normal testes, micropenis, and perineal hypospadias. 
No episodes of hyponatraemia occured. In later life ( 8-10 years ), premature 
adrenarche was diagnosed. Urinary steroid analysis confirmed 36-HSD deficiency 
with higher levels of steroid metabolites than his brother ( Table 2).
Both parents, StaII-2 and Sta II-3, were unaffected.
Fisher suggests that the 36-HSD enzyme deficiency in cases Sta III-l and Sta III-2 is 
present in the testes and adrenals, as poor testosterone response to hCG stimulation 
was observed in both cases and Sta III-2 also demonstrated an impaired cortisol
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response to synacthen. Most of the circulating testosterone was adrenal in origin as 
levels were suppressed by dexamethasone.
Family Pfe ( Fig 10 )
Patients Pfe III-2, Pfe IV-1, Pfe IV-2, and Pfe IV-5 were diagnosed as having mild 
deficiency of 3B-HSD mainly on the basis of having elevated levels of plasma 17- 
hydroxypregnenolone after ACTH stimulation. Patients presented with varying 
degrees of hirsutism and oligomenorrhoea. The mode of inheritance appeared to be 
autosomal dominant, however, X linked inheritance cannot be ruled out. Table 3 
gives a summary of steroid gonadotropin and prolactin values of family Pfe. Table 4 
gives information on the clinical findings for each affected member of the family.
Family Ran ( Fig 11)
Family Ran is characterised by both parents and the two children having marked 
levels of 16 alpha metabolites of 17-hydroxypregnenolone and DHEA suggestive of 
non-salt losing 3B-HSD deficiency ( Table 5 ). The propositus ( Ran HI-3 ) presented 
at age five with a history of clitoral enlargement. No other signs of excess androgens 
were present. Her karyotype was 46 XY indicating that she was in fact a male 
pseudohermaphrodite. Her sister ( Ran III-4 ) had no detectable clinical abnormality 
and had a normal female karyotype ( 46 XX ). Biochemical data on Ran III-4 
indicates that she has the same defect which is likely to manifest itself later in 
females. The mother ( Ran II-7 ) is affected with severe oligomenorrhea (1-2 periods 
per year lasting 2-7 days ) but is not virilised. The propositus was conceived 
spontan eously while her sister was conceived with the help of clomiphene therapy. 
An increase in the 16 alpha hydroxylation of DHEA ( an androgen precursor) to 16 
alpha hydroxy-DHEA ( an oestrogen precursor) may account for the mother's lack of 
virilisation. The father ( Ran H-8 ), though having an abnormal steroid profile had no
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detectable clinical abnormality. Neither Ran III-3, Ran ID-4, Ran II-7, nor Ran II-8 
have disturbances of mineralocorticoid or glucocorticoid metabolism. Comparison of 
steroid profiles indicates that both parents are possibly heterozygotes for the 
deficiency whereas both sibs, who are much more severely affected, are probably 
homozygotes.
FAMILY STA : male pseudohermaphroditism with 
mild salt loss
I 1 O '0 T 0
n
Figure 9
Table 2 ( Family Sta)
Basal
lh post 
ACTH
Low
sodium
diet*
Pre-
HCG**
Post-
HCG***
Cortisol m -i 361 587 <20 <20
09.00, 220-775 nmol/1 IE-2 537 554 21 <20
control 451 881 40 26
17alpha-OHP IH-1 15.7 29.9 1.2 1.3
< 5 nmol/1 m-2 21.2 36.7 1.4 1.3
control 1.3 10.0 <1.0 1.5
Testosterone m -i 0.2 0.2 <0.2 0.6
0.8-1.5 nmol/1 m - 2 1.4 1.4 <0.2 3.3
control 1.4 1.3 <0.2 8.8
DHEA-S ffl-1 6.4 6.3 5.6 3.8
0.3-1.8 umol/1 m - 2 20 21.6 13.2 8.4
control 1.4 1.4 0.3 1.1
Plasma aldosterone, m -i 410 220
recumbent, 100-500 pmol/1 m - 2 350 230
control 120 145
PRA, recumbent, IH-1 6.8 9.9
1.1-2.7 pmol/ml/h IE-2 2.1 5.2
control 2.6 3.0
Urine aldosterone IH-1 16 16.5
10-50 nmol/24h IH-2 18 23
control <10 46
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FAMILY PFE: dominant idiopathic hirsutism
- j i 2 < 5 * o - h
IV 14  24  3<5
4 5 6 76 8
Figure 10
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Table 3 ( Family Pfe)
Steroid 
(reference values +/- SD 
basal/stimulated with 
ACTH)
HI-2
basal 60'
IV-1 
basal 60'
IV-2
basal 60'
IV-5
basal
170H Preg. ng/dl 174 1006 480 2829 259 3062 509
(433 +/- 390/828 +/- 344)
DHEA ng/dl 810 1838 1503||2905| I 306 ||2512 | 1673| |
(868+/-553/1102+/-329)
DHEA-S ug/dl | 259 - 288 - 1 183 | |  - | 486 | |
(286 +/- 120)
170H Prog, ng/dl 119 233 115 | 421 110 | |  216 | 132 |
(149 +/- 98/255 +/- 145)
21 DF ng/dl 11 69 16 | 62 12 41 27
(16 +/- 9/37 +/- 12)
Testosterone ng/dl 39 - 43 | |  - 31 - 56
(31 +/-14)
Androstenedione ng/dl 102 29 423 615 86 159 1 207 | |
(242 +/- 60/270 +/- 99)
Cortisol ng/ml 53 478 157 | 340 97 11 326 68 |
(50-250)
LH 2.0 - 7.2 - 3.4 - 1 1-9
(1.8-13 ng/ml)
FSH 0.8 | |  - | | 4.9 - | 2.0 - 1 29  | |
1-14 U/l
PRL 4.3 - 9 - 5.6 | |  - 1 54  II(2.3-20 ng/ml)
60'
846
72
230
Table 4 ( Family Pfe)
IE-2 IV-1 IV-2 IV-5
Hirsutism +++ ++++ + +
Menarche (years of age) 10 10 12 13
Eumenorrhoea - - + +
Oligomenorrhoea + + - -
Amenorrhoea - - - -
Polycystic ovaries n.i. No No n.i.
Height (cm) 157 162 167 163
Weight (kg) 65 73 69 53
Age (years) 46 22 24 19
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FAMILY RAN
NON SALT-LOSING MALE PSEUDOHERMAPHRODITISM
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Southern blot analysis of DNA from patients and controls
Introduction
The aim of this experiment was to determine how many sequences homologous to 36- 
HSD type I were present in the human genome. It was also hoped that any gross 
rearrangements of DNA in affected families would be detected by this method. 
Genomic DNA from control individuals and from patients were restricted with Xbal 
or EcoRI and resolved on Southern blots probed with 36-HSD type I exon specific 
probes ( Fig 12 ). At the time of this experiment only 36-HSD type I had been 
identified. The restriction enzymes EcoRI and Xbal were chosen because neither cut 
within its coding regions and this was subsequently found to be true for 36-HSD type 
II.
Ikb
3B-HSD type  I
-o 
1
B
PROBE 1/2
Figure 12: Details of hybridisation probes.
Figure 12 shows the extent of the DNA probes used for southern blots.
Results and Discussion
The probes hybridised to several restriction fragments ranging from 0.7 kb to 30 kb ( 
Fig 13 ). For the purposes of presentation, only one example of each enzyme digest is 
shown for each probe. Identical band patterns were observed for each of the patients,
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Sta ID-1, Ran III-3, and Pfe IV-1, and for controls. This indicated that there were no 
detectable gross rearrangements of 36-HSD sequences in these families.
In all cases, fragments of predictable size were observed as intense bands however 
other bands of varying size and intensity were also present. Although some of these 
bands could be pseudogenes the results emphasise the possibility that further 
functional genes for 36-HSD exist in the human genome.
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Figure 13: Southern blot analysis.
36-HSD type I exon specific probes hybridised to several restriction 
fragments ranging from 0.7kb to 30kb. Intense bands were observed which 
corresponded to the sizes predicted by the restriction map of the known 
36-HSD genes.
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Svnonvmons and non-svnonvmous polymorphisms
in tvne 13B-HSD exon 4 ( Fig 14)
Introduction
The full length cDNA of 36-HSD type I was cloned from a lambda g tll placental 
library by Nickson et al 1990. Sequencing of independent clones reveaJed two 
polymorphisms both in exon 4 (Russell et al. 1991a; Russell, et al. 1991b). The first 
polymorphism identified was a RFLP at base 8715 corresponding to codon 338 in 36- 
HSD type I. The substitution of a C for a T resulted in the loss of a Bglll site but no 
change in the amino acid specified. The polymorphism was typed in individual 
samples of DNA by amplifying exon 4 by PCR ( primers (e) and (h) Fig 23 ) and then 
digesting the product with Bglll. The 0.8% agarose gel in Fig 15 shows the 927 bp 
product of exon 4 being reduced in length to 757 bp after digestion with Bglll. 
Homozygote Bglll +/+, homozygote Bglll -/-, and a heterozygote Bglll +/- are 
shown. The second polymorphism was a non-synonymous polymorphism. The 
substitution of an A for a C at base 8803 resulted in the change of amino acid residue 
from Asn to Thr at codon 367 in 36-HSD type I. Table 6 shows the allele frequencies 
of each polymorphic marker. It is not known at present what effect this amino acid 
substitution has on the activity of the enzyme. Initially this polymorphism was more 
difficult and time consuming to detect in individuals as it could only be detected by 
the direct sequencing of PCR products. Figure 16 shows sequence from a homozygote 
Asn, a homozygote Thr, and a heterozygote Asn/Thr. It was later found that DGGE 
could be used as a much more rapid and efficient method for detecting the 
polymorphism at codon 367. The coding sequence of exon 4 was first amplified with 
a 5' GC clamp ( primers (e) and (h) Fig 23 ). When run on DGGE the Thr allele 
migrated to a lower level in the gel than the Asn allele. Fig 17 shows a homozygote 
Asn, a homozygote Thr, and a heterozygote Asn/Thr. The Bglll digestion of exon 4 
PCR products followed by DGGE analysis allowed the haplotypes of each individual 
to be determined. In the case of double heterozygotes i.e. Bgin +- /  367 Asn/Thr this
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proved particularly useful. Fig 18 shows the result of three double heterozygotes who 
all proved to be ( BglII+/Asn ) ( BglII-/Thr).
Together the Bglll and 367 polymorphisms were used to determine the segregation of 
36-HSD type I alleles in the three families ( Ran, Sta, and Pfe ) ( Figs 20, 21, & 22 ) ).
86 nt
3IJ-HSD I
Hfil
1 2
313-HSD II
n- (H I
1 2
Figure 14: Polymorphisms in the genes for 36-HSD types I & II
Figure 14 shows the relative positions of the polymorphisms in 36-HSD 
type I and 36-HSD type II.
Bglll 367 A A C >A C C  
asn >  thr
B I
=  microsatellite
B
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Figure 15: Detection of Bglll RFLP in 3B-HSD type I exon 4.
The substitution of a C for a T at base 8715 resulted in the loss of a Bglll 
site. Figure 15 shows the 927 bp product of exon 4 being reduced in length 
to 757 bp after digestion with Bglll. Homozygote Bglll +/+, homozygote 
Bglll and a heterozygote Bglll +/- are shown.
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iiIiI
367 ' 
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III
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Figure 16: Detection of non-svnonvmous substitution at codon 367 36-HSD type I bv 
direct sequencing of PCR products.
The PCR product was purified on an agarose gel then sequenced using 
Sequenase Version 2.0 (USB) to sequence either the sense strand (top 
row) or anti-sense strand (bottom row) of the DNA. Each sequence track is 
marked with a dot at base 1100. The replacement of A (allele 1) by C 
(allele 2) results in codon 367 changing from Asn to Thr.
ACC
TGG
(AC G T)
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Figure 17: Detection of non-svnonvmous substitution at codon 367 36-HSD type I by 
DGGE.
Figure 17 shows sequence data outlining the codon substitution at residue 
367. The bottom panel shows the separation of 36-HSD type I exon 4 
alleles by DGGE. Homozygotes and heterozygotes are easily identified. 
The gradient of denaturants was 40-60%. The gel was run at 100mA, 80V 
for 20 hours.
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B g l l l  1-----------1-----------1---------- h
AAC"*-
ACC^
Bglll -------
digestion 
product
haplotypes: all C+/A-
Figure 18: H aplotvpe analysis of 3B-HSD type I
Table 6
Genotypes frequency
Alleles:
, M + ................_.................................... 0.5
B gl- .............................. ..................... 0.5
codon 367asn 0.65
codon 367th1 0.35
Haplotvpes:
codon 367asn Bgl + 0.22
codon 361™  Bgl - 0.46
codon 367th1- Bgl + 0.22
codon 367th1 Bg l - 0.07
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Microsatellite marker of the 3B-HSD type II gene
Introduction
A complex set of simple sequence repeats are located in the third intron of 36-HSD 
type II, just 5' to the start of exon 4 ( Fig 14 ). The high number of sequence repeats 
within this small area led us to suspect that this might be a useful source of 
microsatellite variation. Primers (u) and (v) ( Table 8 ) were designed to amplify a 
424bp fragment ( nucleotides 7330 - 7753 ) of 36-HSD type II intron C. PCR 
products of varying length were produced indicating considerable genetic variation 
within this region. The flanking sequence of these amplified segments has been 
determined confirming that amplification was from the expected segment of the 36- 
HSD type II gene, rather than from unrelated genomic segments.
Results
To date 4 alleles have been identified ( Fig 19 ), with the following frequencies ( 20 
unrelated males and females):
allele frequency
1 ( approx 385bp ) 0.48
2 ( approx 425bp ) 0.12
3 ( approx 450bp ) 0.28
4 ( approx 475bp ) 0.12
Alleles were separated on 3% agarose gels. The identification of further alleles by use 
of polyacrylamide gels is expected. The microsatellite analysis of families Ran, Sta, 
and Pfe is shown in Figs 20, 21, and 22.
54
r
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Figure 19: Analysis of 3B-HSD type II intron C microsatellite.
Figure 19 shows the separation of PCR amplified microsatellite DNA on a 
3% agarose gel. Only alleles 1, 3, and 4 are shown.
Track 1: 1/1 homozygote
Track 2: 1/1 homozygote
Track 3: 3/3 homozygote
Track 4: lambda lkb ladder ( Gibco )
Track 5: 1/4 heterozygote
Track 6: 3/3 homozygote
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Results and Discussion: polymorphic markers in 3B-HSD type I and type II 
Ran family
Analysis of the Bglll and codon 367 polymorphisms in 3B-HSD type I and the 
microsatellite in intron C of 3B-HSD type II indicated that both affected sibs, Ran III- 
3 and Ran III-4, inherited the same alleles from either parent i.e. both inherited a
h ^ p to f-yp t hxpLohym
BglII+/Thr/3 from the father and a BglII+/Thr/3 from the mother. The
l\*-ptof’yp4
BglEI+/Thr/3 on the father's side of the family originated from the grandmother 
Ran 1-4. No other individuals on the father's side of the family possessed the
ho~pLoky0€
BglII+/Thr/3 .. On this side of the family only the father, Ran II-8, exhibited an 
abnormal steroid profile ( Table 5 ). The grandmother, Ran 1-4, from whom the Bglll 
allele originated was post menopausal and had reduced adrenal function, therefore no 
conclusions could be drawn from steroid analysis of this individual.
het.pl a kyp t.
The BglII+/Thr/3 from the mother's side of the family was deduced to have 
originated from the grandfather Ran 1-1. All available offspring on this side of the
kout to byp&
family possessed a BglII+/Thr/3 / r , however, only Ran II-6 and Ran II-7 
presented abnormal steroid profiles ( see pglO l). This did not disprove the possibility 
of the BglII+/Thr/j’‘v' i ' ^ being linked to the abnormal phenotype. Our hypothesis is 
that Ran 1-1 was a BglII+/Thr/3, BglII+/Thr/3 homozygote. One BglII+/Thr/3 was 
linked to a mutation in one of the 3B-HSD genes and was passed to Ran II-6, Ran II- 
7, and subsequently to Ran ni-3 and Ran III-4.
Sta family
Analysis of the polymorphic markers in 3B-HSD type I and type II indicated that both 
affected sons inherited the same alleles from either parent i.e. both sons inherited a
h xp lo type  h apU kypt
BglII+/Asn/2 from the father and a BglII+/Thr/l from the mother. No 
other individuals on the father's side of the family possessed the BglII+/Asn/2 ^
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Analysis of the father's side of the family also revealed evidence of a possible 
crossover between the 36-HSD type I and 36-HSD type II genes. The BglII+/Thr/l 
Kaf'ofyoe from the mother's side of the family may have originated from either 
grandparent and may also be present in Sta II-1 who is affected by hirsutism.
Pfe family
Analysis of the microsatellite in intron C of the type II gene indicated that the disease 
phenotype in family Pfe was not linked to 36-HSD type II though the possibility of 
linkage with the type I gene could not be ruled out. Affected individuals Pfe IH-1, IV- 
1, and IV-2, all possessed a Bglll+ZThr/^^^fwhereas IV-5, who was also affected,
ho^fiiotype. ko*p lob/a*.
did not possess the BglII+/Thr/4 . Furthermore, the BglII+/Thr/4 was 
present in Pfe HI-3 who was unaffected.
Figures 20, 21, and 22 show that the polymorphic markers in 36-HSD types I and H co- 
segregate. To date, only one recombination event has been observed between these 
genetic markers ( family Sta, see Fig 21). The LOD scores for these markers were: 3.568 
for Ran, 0.301 for Sta, and 0.301 for Pfe. When combined with families 1 and 2 from 
Rheaume et al.( 1992 ), a total LOD score of 5.374 was obtained indicating tight genetic 
linkage between the two loci ( Table 7 ).
6
0.000 0.001 0.002 0.003 0.004 0.005 0.010 0.020 0.050
Family RAX  
Family S 
Family P 
Rheaume 1 
Rheaume 2
3.568
0.301
0.301
0.602
0.602
3.561
0.300
0.300
0.601
0.601
3.554
0.299
0.299
0.599
0.599
3.548
0.298
0.298
0.598
0.598
3541
0.298
0.298
0597
0.597
3534
0.297
0.297
0596
05%
3.499
0.292
0.292
0585
0.585
3.429
0.283
0.283
0567
0.567
3.216
0.258
0.258
0515
0.515
TOTAL 5.374 5.363 5.350 5.340 5.331 5.320 5.253 5.129 4.762
Table 7: LOD scores for the linkage of the genes for 36-HSD types I and n.
LOD scores were calculated for values of 0 of 0 - 0.05. Values for families 1 
and 2 were computed from the pedigrees of Reaume et al ( 1992).
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FAMILY RAN
NON SALT-LOSING MALE PSEUDOHERMAPHRODITISM
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Figure 20
FAMILY STA  : male pseudohermaphroditism with 
mild salt loss
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Figure 21
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IV 1
FAMILY PFE : dominant idiopathic hirsutism
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Figure 22
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DGGE screening of 36-HSD type I and type II
Introduction
The aim of the following experiments was to detect any sequence variation in the 36- 
HSD type I and II genes which may have accounted for the clinical and biochemical 
symptoms in our patients. PCR fragments from affected patients were compared to 
normal controls using DGGE. In most cases only the most severely affected member 
of each family was screened initially. The computer programmes of Lerman and 
Silverstein ( 1987 ) were used to predict the melting behaviour of each fragment. This 
allowed the design of primers ( Fig 23 ) and the optimisation of DGGE for each of the 
fragments ( Table 8 ). All relevant MELT maps are shown on pages A1-A19.
3R-HSDtype I
Pst I Pst I Bgl II
a b c d e f g h
3R-HSDtype II
i j k I m n o  p
Figure23: PCR primers
Figure 23 shows the relative positions of PCR amplimers used in the 
screening of 36-HSD types I and II by DGGE. The position of relevant 
restriction endonuclease sites is also shown. Further details of PCR primers 
and conditions are given in Table 8.
61
Table 8
36-HSD type I Primers Annealing
temp.
DGGE 
% denaturant
exon 1/2 (a) 1354 - AGTGCATAAAGCTTCAG - 1370
(b) 1855 - CCACATACATGCAGTGT - 1839 50°C 30 - 60%
exon 3 (c) 5655 - CCAATGACCTGACCTGT - 5671
(d) 5881 - CCACCTTGCTGCATCTC - 5865 52°C 55 - 85%
exon 4 (e) 7955 - CGTGGTTGGCACCTCTT - 7971 
(h) 8881 - GGAGCTTGATGACATCT - 8865 52°C 35 - 65%
exon 4A (e) 7955 -CGTGGTTGGCACCTCTT-7971 
(g) 8466 - AGTAGAACTGTCCTCGG - 8450 52°C 40 - 70%
exon 4B (f) 8400 - CACATTCTGGCCTTGAG - 8416 
(h) 8881 - GGAGCTTGATGACATCT - 8865 52°C 40 - 65%
36-HSD type II
exon 1/2 (i) 1219 - AG AGC AT A A AGCTCC AG - 1235 
(j) 1720 - CCACACCCATGCAGAGT - 1704 50°C 30 - 60%
exon 3 (k) 5488 - CCAATGACCTGACCTGT - 5504 
(1) 5714 - CCAACTTG'ITTTATCTC - 5698 48°C 35 - 65%
exon 4A (m) 7849 - TGTGGTTGCAGCTCCTT - 7865 
(o) 8270 - AGACTGGGTTGACTGAT - 8254 50°C 45 - 75%
exon 4B (n) 8181 - GCCCATTCCTTTCTGCC - 8197 
(p) 8774 - GAGTTTGATGACATTTC - 8758 49°C 40 - 70%
0 specific (q) 5662 - CCTGACCTGTGTTCTTG - 5678 
(r) 5786 - AGGCGGTGCGGATGACT - 5770 52°C
intron B > 0 (s) 5269 - CATGATGCTGGAGTCCC - 5285 
(r) 5786 - AGGCGGTGCGGATGACT - 5770 52°C
0 > intron C (q) 5662 - CCTGACCTGTGTTCTTG - 5678 
(t) 6268 - GTGACTACAGTGGCACC - 6252 52°C
microsatellite (u) 7330 - CTCAGAGTATAGCCTCC - 7346 
(v) 7753 - ATG AT AC AGCCGT AGG A - 7737 52°C
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DGGE screening of 3B-HSD type I exon 1/2
Exons 1 and 2 extend over only 414 bp and were therefore initially amplified with 
intron A as a single segment ( nt 1354 - 1855 ). This PCR product was initially 
screened with a GC clamp at the 5' end and then at the 3' end. According to the melt 
map (A2) the 3’ GC clamped product was predicted to comprehensively screen the 
lowest melting domain of the molecule ( nt 1354 - 1567 ) although nucleotides 1568 
to 1855 would not be screened as thoroughly. Digestion of the 3' GC clamped product 
with PstI resulted in the reduction in size of the lower melting domain from 214 bp to 
91 bp. This increased the effectiveness of the screening of nucleotides 1568 to 1855 
(A3).
Results
When exon 1/2 type I was amplified with a 5' GC clamp, Pfe, Ran, and Sta samples 
showed no difference in migration on DGGE. When the PCR product was cut with 
PstI all control and patient samples again yielded a band of similar mobility.
When amplified with a 3' GC clamp, Ran and Sta samples produced a single band on 
DGGE which corresponded to controls. All three available members of family Pfe ( 
Pfe m-2, Pfe IV-1, Pfe IV-2 ) produced this same band ( A ) plus a second band ( B ) 
which resolved at a higher level in the gel i.e. a lower Tm ( Fig 24).
PCR product from Pfe IV-1 containing both bands A and B was cloned into pT7 Blue 
T-vector and putative clones were identified by blue/white selection. The presence of 
insert in these samples was confirmed by PCR. PCR product from a number of 
positive clones were run on DGGE alongside control Pfe IV-1 DNA. A number of 
clones corresponding in migration to bands A and B were detected and in addition 
several clones were present whose migration did not correspond to bands A and B (
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Fig 25 ). When digested with PstI, clones 5 and 6 ( bands B and A respectively ) 
migrated with the other cut samples ( Fig 26 ). This indicated that the sequence 
variation between the two clones was most likely to be located in the segment which 
was deleted by the PstI digestion i.e. nt 1354 - 1476.
Sequencing of clones 5 ( band B 1 and 6 ( band A )
Each clone was sequenced over its entire length using primers (a) and (b) ( Fig 23 ). 
Clone 6 ( band A ) showed no differences when compared to the published sequence. 
Clone 5 ( band B ) showed one base difference when compared to the published 
sequence, a C > A substitution at base 1426 ( Fig 27 ) i.e. within the untranslated 
exon 1. No other sequence variations were found in this clone. The location of the 
substitution, between bases 1354 and 1476, was as predicted.
Screening of extended family Pfe
When screened for the C > A substitution in exon 1, Pfe III-1, Pfe IV-3, and Pfe IV-5 
showed no difference in migration when compared to controls. Pfe III-3 produced 
both bands A and B indicating the presence of the C > A substitution in exon 1.
Discussion: type I exon 1/2
According to computer predictions (A2) the screening of full length exon 1/2 with a 
3'GC clamp should have comprehensively screened the lower melting domain of the 
PCR product i.e. nt 1354 - 1567. This analysis resulted in the detection of a C > A 
substitution at nt 1426 in the three available members of the Pfe family ( Pfe III-2, 
IV-1 & IV-2 ). As the substitution was present in the untranslated exon 1 it was 
unlikely to be the cause of the 36-HSD deficiency in this family, however as all three
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affected members possessed the same substitution it was hoped that it may show 
linkage with the phenotype in other affected members of the same family. When an 
extended family was finally obtained it was found that Pfe IV-5, the other affected 
member of the family, did not contain the C > A substitution in exon 1. It was also 
shown that Pfe III-3, an unaffected member of the family, did contain the C > A 
substitution. The polymorphic markers in 36-HSD types I and II strongly suggest that 
neither 36-HSD type I nor type II is linked to the disease phenotype in family Pfe.
The methods used in the detection cloning and confirmation of clones proved 
effective. According to the DGGE pattern the sequence variation in Pfe samples was 
expected to reduce the Tm of the molecule. This prediction was confirmed by the 
eventual identification of the C > A substitution. The location of the substitution 
between nt 1354 and 1476 was accurately predicted initally by the melt maps (A2 & 
A3) and later by the PstI digestion of samples ( Fig 26 ). The need to screen positive 
clones on DGGE before sequencing was clearly necessary as 6 out of 11 positive 
clones tested did not co-migrate with bands A and B ( Fig 25 ). These spurious PCR 
products were most probably the result of Taq polymerase errors during the initial 
amplification from Pfe genomic DNA.
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Figure 24: DGGE gel showing the migration of 36-HSD type I exon 1/2
(+) = control patient. Tracks 2-5 contain samples Pfe IV-1, Pfe IV-2, Ran 
III-3 and Sta III-1 respectively. Bands A and B are identified at left hand 
side.The gradient of denaturants was 30-60%. The gel was run at 100mA, 
80V for 20 hours.
B 
A
Clone 1 2 3 4 5  6 7 8 9 1 0 1 1
Figure 25: Selection of positive clones bv DGGE ( 3B-HSD type I exon 1/2 )
Track 6 contains Pfe IV-1 exon 1/2 as a positive control. Bands A and B 
are identified at left hand side. The gradient of denaturants was 30-60%. 
The gel was run at 100mA, 80V for 20 hours.
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Figure 26: PstI restriction analysis of Pfe IV-1 clones ( 3B-HSD type I exon 1/2 )
Clones 5 ( band B ) and 6 ( band A )( Fig 25 ) were re-run in tracks 1 and 
2 respectively. Tracks 3 and 4 contain clones 5 and 6 both cut with Pst I. 
No difference in migration is observed after Pst I digestion. (+) = control 
sample digested with PstI. Bands A, and B are identified at left hand side. 
The gradient of denaturants was 30-60%. The gel was run at 100mA, 80V 
for 20 hours.
3R-HSDtype I
C > A  nt 1426 
PstI
a b
Figure 27: Nucleotide substitution in 36-HSD type I exon 1.
Figure 27 shows the relative position of the nucleotide substitution in 36- 
HSD type I exon 1. The substitution of an A for a C at base 1426 has to 
date only been detected in family Pfe. The position of the relevant PCR 
primers and of the Pst I restriction site are also shown.
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DGGE screening of 3B-HSD tvoe I exon 3
The melting profiles of type I exon 3 (A4 & A5) indicated a single melting domain 
from nt 5655 - 5881. Screening first with a 5'GC clamp then with a 3'GC clamp 
should have been adequate for detecting >99% of all possible mutations.
Using a 3'GC clamp on the PCR product, all samples produced one band which 
migrated to the same depth in gel as controls.
With a 5'GC clamp, PCR products of exon 3 produced two bands & and B. All three 
available Pfe samples ( Pfe III-2, IV-1, and IV-2 ) also produced a third band 0 ( Fig 
28 ). Bands &, B, and 0 were cut from the gel and reamplified by PCR. PCR products 
were run on an identical gel to confirm successful isolation. Each PCR product was 
then sequenced directly. The sequence obtained from & and B was poor but both 
showed homology to 3B-HSD. Sequence from band 0 was of better quality and 
showed a number of sequence variations when compared to 3B-HSD type I. Of 132 
bp sequenced, 13 substitutions were detected, 3 in intron B and 10 in exon 3 ( Fig 29 
).
Cloning and sequencing of 3B-HSD type I exon 3 DGGE variants 
To obtain more extensive sequence of &, B, and 0, the bulk type I exon 3 5'GC PCR 
product from Pfe IV-1 ( unseparated by DGGE ) was cloned into pT7 Blue T-vector 
and putative clones were identified by blue/white selection. The presence of insert in 
these samples was confirmed by PCR. To date 4 independent clones have been 
identified. Clone 1 was found to be identical to the published 3B-HSD sequence. 
Clone 2 was found to be identical to the previous sequence obtained from band 0 ( 
Fig 29 ). Complete sequence of 0 revealed an open reading frame ( ORF ) of 165bp. 
Clones 3 and 4 were also shown to have ORFs of 165bp. Comparisons of 3B-HSD 
type I and type II with clones 2 ( 0), 3, and 4 are shown in Figures 30 and 31. Clone 2
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( 0 ) differs from type I in 23 nucleotides and 9 amino acids and from type II in 24 
nucleotides and 9 amino acids. Clone 3 differs from type I in 18 nucleotides and 9 
amino acids and from type II in 26 nucleotides and 9 amino acids. 16 of the 
nucleotide substitutions and 8 of the amino acid substitutions observed were also 
present in clone 2 (0 ) .  Clone 4 showed much more homology to 36-HSD type I than 
either clones 2 or 3. Only 9 nucleotides and 4 amino acid differences were observed 
when compared to 36-HSD type I. 19 nucleotide and 4 amino acid substitutions were 
observed when compared to type II.
Clones 1, 3, and 4 were run on DGGE alongside controls ( amplified from Pfe IV-1 
genomic DNA ) to determine if any of them corresponded to bands §l or 6 ( Fig 32 ). 
Clone 1 co-migrated with band L No clone was isolated which corresponded to band 
6 although clone 3 migrated to a similar level in the gel. Clone 4 migrated to a lower 
level in the gel than either of bands &, 6, or 0. There were too many mutations present 
in clone 4 for it to have been the result of Taq polymerase errors, also its 3' end was 
not a direct copy of any of the other clones, therefore it was unlikely to have 
originated through "jumping PCR" ( the small size of the product also makes 
"jumping PCR" an unlikely explanation ). The most likely explanation is that clone 
4 is a legitimate copy of a sequence that occurs in the genome and that it did not 
appear on the original DGGE gel simply because it was not amplified to a sufficient 
concentration.
Investigation of 0
All three available members of the Pfe family ( Pfe III-2, IV-1, and IV-2 ) produced 
an extra band ( 0 ) on DGGE and it was hoped that 0 might account for the clinical 
and biochemical symptoms in family Pfe. The high number of base substitutions 
present in 0 made it very unlikely that 0 was the result of spontaneous mutation of 
either the 36-HSD type I or type II genes. It was our hypothesis that 0 originated
70
elsewhere in the genome. To test our hypothesis on the origin of 0, primers were 
designed which would specifically amplify 0 ( Fig 33 ). The aim of this experiment 
was to find if 0 could be amplified from unaffected individuals and not only from 
family Pfe. In a further experiment, PCR primers were designed to sit on intronic 
sequence flanking 36-HSD type I exon 3 ( Fig 33 ). It was hoped that by using a 
combination of these primers and 0 specific primers an insight may be gained as to 
whether 0 was attached to the type I gene in family Pfe as a result of DNA 
rearrangement.
Results
The amplification of a putative 0 band (125 bp ) using 0 specific primers is shown in 
Figure 34. It was shown that this fragment could be amplified from unaffected 
individuals and not only from family Pfe. The 125 bp PCR product was cloned into 
pT7 Blue T-vector and putative clones identified by blue/white selection. Positive 
clones were confirmed by PCR. Sequencing of clones revealed identical sequence to 
the 0 band of family Pfe. Primers (s) and (r), and (q) and (t) were unsuccessful in 
amplifying a 36-HSD type 1-0  hybrid product.
Discussion: type I exon 3
The use of 0 specific primers showed that 0 was present in the genome of unaffected 
individuals and not only family Pfe.
The appearance of 0 in only one family ( Pfe ) when primers (c) and (d) were used 
could be explained by the following possibilities. It was possible that the 0 sequence 
originated from a pseudogene or even from another functional 36-HSD gene. The
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primers used would not normally have amplified 0 , however, in family Pfe a point 
mutation at one of the intronic primer sites could have resulted in the amplification of 
0. If this was the case then 0 was unlikely to be the cause of the deficiency in family 
Pfe. Another possibility was that some sort of DNA rearrangement may have 
occurred in the Pfe family between either of the known genes and another functional 
36-HSD gene or pseudogene. This hypothesis was unlikely as no evidence of gross 
rearrangement was observed on southern blots ( Fig 13 ). If rearrangement had 
occurred, the type I gene would be the most likely candidate for rearrangement as 0 
was amplified using type I specific primers.
The attempt at linking 0 to 36-HSD type I by using a combination of intronic primers 
and 0 specific primers failed to produce a PCR product. This may mean that 0 was not 
linked to 36-HSD type I although it is still possible that some form of DNA 
rearrangement may have occurred and that the boundaries of such a rearrangement 
were outwith the intronic primer sites.
The identification of four separate clones homologous to 36-HSD type I and type II 
supports the previous southern blot data indicating the existence of other 36-HSD 
sequences within the genome. It is not known if these clones have originated from 
pseudogenes or from functional genes, each one has an ORF and each clone extends 
into intronic sequence indicating that they have not originated from processed 
pseudogenes.
Figure 28: DGGE gel showing the migration of human 3B-HSD type I exon 3.
(+) = control patient. Tracks 2, 3, and 4 contain samples Ran III-3, Sta III- 
1, and Pfe IV -1 respectively. Bands B and 0 are identified at the left 
hand side. The gradient of denaturants was 55-85%. The gel was run at 
100mA, 80V for 20 hours.
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Figure 29: Direct PCR sequence of band 0.
Figure 29 shows the sequence of part of band 0 obtained by direct 
sequencing of PCR product. Nucleotides that do not match with the known 
sequence of 313-HSD type I exon 3 are written in left margin (0) with the 
corresponding wild type (+) nucleotide in the far left margin of the
sequence.
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36-HSD I 
36-HSD II 
Clone 2(0) 
Clone 3 
Clone 4 
Consensus
TCACACAGAA 
TCACACAGAG 
TCTTGCAGAG 
TCACACAGAA 
TCTTGCAGAG 
TC ...CAGA.
CTCCAGAACA
CTCCAGAACA
CTCCAGAACA
CTCCAGAACA
CTCCAGAACA
CTCCAGAACA
AGACCAAGCT 
GGACCAAGCT 
AGACCAAGAT 
AGACCAAGCT 
AGACCAAGAT 
AGACCAAG.T
GACAGTGCTG 
GACTGTACTT 
GACAGTGCTA 
GACAGTGCTG 
GACAGTGCTA 
GACAGTGCT.
GAAGGAGACA
GAAGGAGACA
GAAGGAGACA
GAAGGAGACA
GGAGGAGACA
GaAGGAGACA
36-HSD I 
36-HSD II 
Clone 2(0) 
Clone 3 
Clone 4 
Consensus
TTCTGGATGA 
TTCTGGATGA 
TTCTGGATCA 
TTCTGGATCA 
TTCTGGATGA 
TTCTGGAT.A
GCCATTCCTG
GCCATTCCTG
GTCATGCCTG
GTCATGCCTG
GCCATTCCTG
G.CAT.CCTG
AAGAGAGCCT
AAAAGAGCCT
AAGAGAGCCT
AAGAGAGCCT
AAGAGAGCCT
AAGAGAGCCT
GCCAGGACGT 
GCCAGGACGT 
GCCAGGACAT 
GCCAGGACAT 
GCCAGGACGT 
GCCAGGAC.T
CTCGGTCATC 
CTCGGTCGTC 
CTCGGTAGTC 
CTCGGTAGTC 
CTCGGTCGTC 
CTCGGT.gTC
36-HSD I 
36-HSD II 
Clone 2(0) 
Clone 3 
Clone 4 
Consensus
ATCCACACCG
ATCCACACCG
ATCCACACCG
ATCCACACCG
ATCCGCACCG
ATCCaCACCG
CCTGTATCAT 
CCTGTATCAT 
CCTCTATCAT 
CCTCTATCAT 
CCTGTATCAT 
CCT.TATCAT
TGATGTCTTC 
TGATGTCTTT 
TGACATCTTT 
TGACATCTTC 
TGATGTCTTC 
TGA..TCTTc
GGTGTCACTC
GGTGTCACTC
GGTGTCACTC
GATGTCACTC
GGTGTCACTC
GgTGTCACTC
ACAGAGAGTC
ACAGAGAGTC
ACAGAGAGTC
ACAGAGAGTC
ACAGAGAGTC
ACAGAGAGTC
36-HSD I 
36-HSD II 
Clone 2(0) 
Clone 3 
Clone 4 
Consensus
TATCATGAAT 
CATCATGAAT 
TATCATGAAC 
TATCATGAAC 
TATCATGAAT 
TATCATGAA.
GTCAATGTGA 
GTCAATGTGA 
TTCAACGTGA 
TTCAACGTGA 
GTCAATGTGA 
.TCAA.GTGA
AAGGTATGGT 
AAGGTACAGT 
AAGGTACAGT 
AAGGTACAGT 
AAGGTATGGT 
AAGGTA..GT
AGGCTGGGGA
AGCCTGGGGA
AGCCTGAGGA
AGCCTGAGGT
AGGCTGGGGA
AG.CTG.GGa
GGAGATGCAG
GGAGATAAAA
GGAGATGCAG
GGAGATGCAG
GGAGATGCAG
GGAGATGCAG
36-HSD I 
36-HSD II 
Clone 2(0) 
Clone 3 
Clone 4 
Consensus
5874
CAAGGTG 
CAAGTTGG 
CAAGGTGG 
CAAGGTGG 
CAAGGTG 
CAAGGTGG
Figure 30: Nucleotide sequence comparison of clones 2-4 
( Pfe IV-1: 36-HSD type I exon 3s)
Figure 30 shows a comparison of clones 2-4 ( Pfe IV-1: 36-HSD type I 
exon 3) with the nucleotide sequences of 36-HSD types I and II. Clone 1 
was found to be identical to the published sequence of 36-HSD type I.
codon 50
36-HSD I 
36-HSD II
LQNKTKLTVL
LQNRTKLTVL
Clone 2(0) LQNKTKMTVL
Clone 3 
Clone 4 
Consensus
LQNKTKLTVL 
LQNKTKMTVL 
LQNKTK.TVL
EGDILDEPFL 
EGDILDEPFL 
EGDILDQSCL 
EGDILDQSCL 
GGDILDEPFL 
eGDILD...L
KRACQDVSVI 
KRACQDVSW 
KRACQDISW 
KRACQDISW 
KRACQDVSW 
KRACQD.SVv
IHTACIIDVF
IHTACIIDVF
IHTASIIDIF
IHTASIIDIF
IRTACIIDVF
IhTA.IID.F
GVTHRESIMN
GVTHRESIMN
GVTHRESIMN
DVTHRESIMN
GVTHRESIMN
gVTHRESIMN
codon 100 
36-HSD I VNVK 
36-HSD II VNVK 
Clone 2(0) FNVK 
Clone 3 FNVK 
Clone 4 VNVK 
Consensus NVK
Figure 31: Protein sequence comparison of clones 2-4 
( Pfe IV-1: 36-HSD type I exon 3 ^
Figure 31 shows a comparison of clones 2-4 ( Pfe IV-1: 36-HSD type I 
exon 3) with the protein sequence of 36-HSD types I and II.
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Figure 32: DGGE analysis of clones 1. 3. and 4 ( Pfe IV-1: 3B-HSD type I exon 31
Tracks 3, 5, and 6 contain bands k, 6, and 0 amplified from Pfe IV -1 
genomic DNA.
Tracks 2 and 4 contain PCR product amplified from clone 1.
Track 1 contains PCR product amplified from clone 4.
Track 7 contains PCR product amplified from clone 3.
Bands k, 6 and 0 are identified at the right hand side. The gradient of 
denaturants was 55-85%. The gel was run at 100mA, 80V for 20 hours.
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200bp
36-HSD type I ^r~ 36-HSD type I
intron B intron C
Figure 33: The relative position of primers used in the investigation of band 0.
Primers (q) and (r) are 0 specific. Primers (s) and (t) are 36-HSD type I 
specific. Further details of PCR primers and conditions are given in Table 
8 .
Figure 34: Investigation of band 0.
a) Amplification of the 125bp band 0 from 3 unaffected individuals. 
Samples were chosen randomly from a panel of unrelated individuals. 
Track 4 contains band 0 amplified from Pfe IV-2 as a positive control. 
Track 5 contains lambda lkb size marker ( Gibco ).
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PGGE-SCr££DiOSOtl0-H§D type I exQn 4
In the following experiments part of the coding sequence of 36-HSD type I plus a 
small amount of flanking non-coding sequence was screened by DGGE. The majority 
of the 3' untranslated portion of the gene was not screened.
The melt maps of exon 4 indicated that a full length PCR product of 964 bp ( primers 
(e) & (h) Fig 23 ) would be poorly screened by DGGE (A6 & A7). Therefore it was 
decided to use a combination of primers and enzyme digestions to screen exon 4 
thoroughly (A8-11). The amplification of a 964 bp 5GC clamped product would have 
resulted in the inadequate screening of bases 7955 - 8460 by DGGE. The same PCR 
product when digested with PstI resulted in the screening of bases 8000 - 8420 by 
DGGE (A8). The use of primers (e) and (g) to amplify a 3' GC clamped product of 
549bp resulted in the screening of bases 7955 - 8420 by DGGE (A9). An attempt was 
made to screen bases 8400 - 8881 by DGGE using PCR primers (f) and (h) however 
this proved to be unsuccessful. In the following results nucleotides 7955 - 8466 are 
referred to as exon 4A. An overlapping fragment of nucleotides 8400 - 8881 is 
referred to as exon 4B.
Results
When the 5' GC clamped product of exon 4 was digested with PstI, all samples ( Pfe, 
Ran, and Sta ) produced one band which migrated to the same depth in gel as 
controls. Similarly, when either primers (e) and (g) ( exon 4A 3GC ), or (f) and (h) ( 
exon 4B 5G C ) were used, all samples ( Pfe, Ran, and Sta) produced one band which 
migrated to the same depth in gel as controls.
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Only when exon 4B was amplified with a 3'GC clamp was any difference in 
migration observed on denaturing gels ( Fig 35 ). The Ran sample ( Ran III-3 ) 
produced one band ( A ) which migrated to the same depth in gels as controls.
The Sta sample (S ta III-l ) produced one band ( A ) which migrated to the same 
depth in gels as controls, plus an extra band ( B ) which resolved at a higher level in 
the gel i.e. a lower Tm. When other available members of the Sta family were run on 
a similar gel, samples Sta III-2 and Sta H-3 produced an identical pattern to Sta III-l. 
Sta II-2 produced one band ( A ) which migrated to the same depth in gels as controls. 
The PCR product of Sta III-l was cloned into pT7 Blue T-vector and putative clones 
identified by blue white selection. The presence of insert in these clones was 
confirmed by PCR. PCR product from positive clones was run on DGGE alongside 
Sta control samples. Clones which co-migrated with bands A and B were selected for 
sequencing. PCR products which did not co-migrate with bands A or B were also 
observed.
The Pfe sample ( Pfe III-2 ) produced a single band ( C ) which migrated to a lower 
depth in gel than controls i.e. a higher Tm. When other available members of the Pfe 
family were run on a similar gel, both Pfe IV-1 and Pfe IV-2 produced the same band 
as Pfe III-2 plus a second band ( A ) which migrated to the same depth in gel as 
controls. The PCR product of Pfe III-2 was cloned into pT7 Blue T-vector and 
putative clones identified by blue white selection. The presence of insert in these 
clones was confirmed by PCR. PCR product from positive clones was run on DGGE 
alongside Pfe control samples and clones which co-migrated with bands A and C 
were selected for sequencing . PCR products which did not co-migrate with bands A 
or C were also observed.
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Sequencing of clones
The sequence obtained from clones is shown in figure 36. All of the clones contained 
numerous sequence variations when compared to 36-HSD type I exon 4. The 
corresponding protein sequence of each clone shows that stop codons were present in 
all cases ( Fig 37 ).
Discussion: type I exon 4
No sequence variation in exon 4A of 36-HSD type I was found in any of the families 
but analysis of exon 4B gave an unexpected result. It appears that the primers used 
amplified a different 36-HSD sequence to the one expected. The DGGE results 
suggested that Sta III-l, El-2, and II-3 possessed one normal allele ( band A ) and one 
mutant allele ( band B ). Pfe IV-1 and IV2 appeared to possess one normal allele ( 
band A ) and one mutant allele ( band C ), and Pfe III-2 appeared to possess two 
mutant alleles ( both band C ). The Ran sample ( Ran EI-3 ) and the control samples 
only produced band A.
Sequencing revealed that none of the bands observed on DGGE were 36-HSD type I 
exon 4. All clones examined were homologous to 36-HSD type I however each had a 
series of point mutations present. Some of these point mutations would have resulted 
in the introduction of stop codons into the the coding sequence of 36-HSD. It is 
probable that these sequences were amplified from pseudogenes. The only bands to 
appear on DGGE were the bands which were cloned and none of these bands was the 
expected 36-HSD exon 4. There is no easy explanation as to why this happened as 
even if pseudogenes were amplified 36-HSD exon 4 should also have been amplified.
The 3' half of exon 4 ( nt 8460 - 8881 ) has already been screened for each of the 
families during the analysis of the non-synonymous polymorphism at codon 367 ( see
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pg47 ). This analysis involved the screening of a full length exon 4 PCR product 
amplified with a 5'GC clamp. Although no mutations were detected in any of the 
families it would have been preferable to screen this region of exon 4 using a shorter 
PCR product.
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Figure 35: DGGE gel showing the migration of human 3B-HSD type I exon 4B.
(+) = control patient. Tracks 1-8 contain samples Pfe ni-2, Pfe IV -1, Pfe 
IV-2, (+), Ran III-3, Sta III-l, Sta III-2, and (+) respectively. The gradient 
of denaturants was 40-65%. The gel was run at 100mA, 80V for 20 hours. 
Bands A, B, and C are identified at the left hand side.
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315-HSDI 
36-HSDII 
Band A 
Band B 
Band C 
Consensus
8450
CCGAGGACAG TTCTACTATA 
CCGAGGTCAA TTCTATTACA 
CCTAGGACAG TTCTACTATA 
CCTAGGACAG TTCTACTATA
C C .AGGaCAg TTCTAcTAtA
TCTCAGATGA
TCTCAGATGA
TCTCAGATGA
TCTCAGATGA
TCAGATGA
TCTCAGATGA
CACGCCTCAC
CACGCCTCAC
CACGCCTCAC
CACGCCTCAC
CACGCCTCAC
CACGCCTCAC
CAAAGCTATG
CAAAGCTATG
CAAAGTTATG
CAAAGTTATG
CAAAGTTATG
CAAAGtTATG
3S-HSDI 
3E-HSDII 
Band A 
Band B 
Band C 
Consensus
8500
ATAACCTTAA
ATAACCTTAA
ATAACCTTAA
ATAACCTTAA
ATAACCTTAA
ATAACCTTAA
TTACACCCTG
TTACATCCTG
TTACATCTTG
TTACATCCTG
TTACATCCTG
TTACAtCcTG
AGCAAAGAGT
AGCAAAGAGT
AGCAAAGAGT
AGCAAAGAGT
AGCAAAGAGT
AGCAAAGAGT
TCGGCCTCCG
TTGGCCTCCG
TCGGCCCCTG
TCGGCTCCTG
TCGGCCCCTG
TcGGCccCtG
CCTTGATTCC
CCTTGATTCC
CCTTGATTCC
CCTTGATTCC
CCTTGATTCC
CCTTGATTCC
3S-HSDI 
3S-HSDII 
Band A 
Band B 
Band C 
Consensus
8550
AGATGGAGCT
AGATGGAGCC
AGATGAAGCC
AGATGAAGCC
AGATGAAGCC
AGATGaAGCc
TTCCTTTATC
TTCCTTTAAC
TTCTTTTATT
TTCTTTTATT
TTCTTTTATT
TTCtTTTAtt
CCTGATGTAT
CCTGATGTAC
CCTGATGTAC
CCTGATGTAC
CCTGATGTAC
CCTGATGTAC
TGGATTGGCT
TGGATTGGCT
TGGATTGGCT
TGGATTGGCT
TGGATTGGCT
TCCTGCTGGA
TCCTGCTGGA
TCCTGCTGGG 
TCCTGCTGGG 
TCCTGCTGG.
8697
3&-HSDI 
36-HSDII 
Band A 
Band B 
Band C 
Consensus
AAGAAGGCTC
AAGAAGGCTC
AAGAAGGCTC
AAGAAGGCTC
AAGAAGGCTC
AAGAAGGCTC
AGCGAGATTT
AGCGAGATCT
AGCGAGATCT
AGCGAGATCT
AGCGAGATCT
AGCGAGATCT
GGCGTATAAG
GGCGTATAAG
GGCATATAAG
GGCATATAAG
GGCATATAAG
GGCaTATAAG
CCACTCTACA
CCACTCTACA
CCACTTTACA
CCACTTTACA
CCACTTTACA
CCACTtTACA
GCTGGGAGGA
GCTGGGAGGA
GCTGGGAGGA
GCTGGGAGGA
GCTGGGAGGA
GCTGGGAGGA
8747
35-HSDI
36-HSDII 
Band A 
Band B 
Band C 
Consensus
AGCCAAGCAG
AGCCAAGCAG
AGCCAAGCAG
AGCCAAGCAG
AGCCAAGCAG
AGCCAAGCAG
AAAACGGTGG
AAAACCGTGG
AAAACCATGG
AAAACCATGG
AAAACCATGG
AAAACcaTGG
AGTGGGTTGG
AGTGGGTTGG
AGTGAGTTGG
AGTGAGTTGG
AGTGAGTTGG
AGTGaGTTGG
TTCCCTTGTG
TTCCCTTGTG
TTCCCTTGTG
TTCCCTTGTG
TTCCCTTGTG
TTCCCTTGTG
GAC CGGCACA 
GAC CGGCACA 
GACCGGCACA 
GACCGGCACA 
GACCGGCACA 
GACCGGCACA
8797
3S-HSDI 
3S-HSDII 
Band A 
Band B 
Band C 
Consensus
AGGAGAACCT
AGGAGACCCT
AGGAGAACCT
AGGAAAACCT
AGGAGAACCT
AGGAgAaCCT
GAAGTCCAAG
GAAGTCCAAG
GAAGTCCAAG
GAAGTCCAAG
GAAGTCCAAG
GAAGTCCAAG
ACTCAGTGAT
ACTCAGTGAT
ACTCAGTGCT
ACTCAGTGCT
ACTCAGTGCT
ACTCAGTGcT
TTAAGGATGA
TTAAGGATGA
TTAAGGATGA
TTAAGGATGA
TTAAGGATGA
TTAAGGATGA
CAGAGATGTG
CAGAGATGTG
CAGAGATGTG
CAGAGATGTG
CAGAGATGTG
CAGAGATGTG
Figure 36: Nucleotide sequence of clones ( 36-HSD type I exon 4B ^
Figure 36 shows the nucleotide sequence of clones detected during the 
analysis of 36-HSD type I exon 4B by DGGE. When compared to 36-HSD 
type I exon 4, all clones contained numerous sequence variations.
codon 250
3S-HSDI 
3E-HSDII 
Band A 
Band B 
Band C 
Consensus
RGQFYYISDD
RGQFYYISDD
LGQFYYISDD
LGQFYYISDD
SDD
.GQFYYISDD
TPHQSYDNLN
TPHQSYDNLN
TPHQSYDNLN
TPHQSYDNLN
TPHQSYDNLN
TPHQSYDNLN
YTLSKEFGLR
YILSKEFGLR
YILSKEFGPC
YILSKEFGSC
YILSKEFGPC
YiLSKEFG.c
LDSRWSFPLS 
LDSRWSLPLT 
LDSR*SLLLF 
LDSR*SLLLF 
LDSR*SLVLF 
LDSR*S1.Lf
LMYWIGFLLE
LMYWIGFLLE
LMY
LMYWIGFLL
LMYWIGFLLG
LMYWIGFLLe
codon 332
3E-HSDI 
3S-HSDII 
Band A 
Band B 
Band C 
Consensus
KKAQRDLAYK
KKAQRDLAYK
KKAQRDLAYK
KKAQRDLAYK
KKAQRDLAYK
KKAQRDLAYK
PLYSWEEAKQ
PLYSWEEAKQ
PLYSWEEAKQ
PLYSWEEAKQ
PLYSWEEAKQ
PLYSWEEAKQ
KTVEWVGSLV
KTVEWVGSLV
KTME*VGSLV
KTME*VGSLV
KTME*VGSLV
KTME*VGSLV
DRHKENLKSK
DRHKETLKSK
DRHKENLKSK
DRHKENLKSK
DRHKENLKSK
DRHKENLKSK
TQ*FKDDRDV
TQ*FKDDRDV
TQCFKDDRDV
TQCFKDDRDV
TQCFKDDRDV
TQCFKDDRDV
Figure 37: Protein sequence of clones ( 36-HSD type I exon 4B )
Figure 37 shows the protein sequence of clones detected during the 
analysis of 36-HSD type I exon 4B by DGGE. Stop codons were present 
in all clones.
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DGGE screening of 3B-HSD type TT exon 1/2
Exons 1 and 2 extend over only 416bp and were therefore co-amplified with intron A 
as a single segment ( nt 1219 - 1720 ). Using primers (i) and (j) a 5'GC clamped 
product was amplified. When run on DGGE this resulted in the screening of bases 
1250 - 1480 and 1590 - 1720 (A12). The 3'GC clamped product resulted in the 
screening of bases 1219 - 1430 (A13).
In both cases all samples, Pfe, Ran, and Sta produced one band which migrated to the 
the
same depth in’gel as controls.
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DGGE screening of 3R-HSD tvne IT exon 3
The melting profiles of type II exon 3 (A 14 & A15) indicated a single melting domain 
from nt 5488 - 5714. Screening first with a 5'GC clamp then with a 3'GC clamp 
should have been adequate for detecting >99% of all possible mutations.
When amplified with a 5GC clamp, samples Pfe, Ran, and controls produced a single 
band ( A ). The Sta sample ( Sta ID-1) produced the same band ( A ) plus three extra 
bands, band B which migrated to a lower depth in the gel i.e. a higher Tm than 
controls, and bands C and D which appeared as a doublet resolving at a higher level 
in the gel i.e. a lower Tm than controls ( Fig 38 ).
Samples amplified with a 3GC clamp produced a similar result. This experiment run 
on the same gel showed the 3GC clamped products resolving at a lower point in the 
gel than the 5' GC clamped products. Once again Pfe and Ran samples migrated to the 
same depth in gel as controls. Sta III-1 produced the same four bands as before only 
this time the separation of bands C and D was more pronounced.
Screening of family Sta
When run on a similar gel 5GC clamped samples of Sta III-2 and Sta II-2 produced 
the same four bands as Sta III-1. Sta 1-1, II-l, II-3, II-4, and D-5 all produced a single 
band which migrated to the same depth in gel as band A.
PCR product from Sta III-l was cloned into pT7 Blue T-vector and putative clones 
identified by blue/white selection. The presence of insert in these clones was 
confirmed by PCR. Clones which corresponded to bands A and B on DGGE ( Fig 39 
) were selected for sequencing ( clones 8 and 10, and 9 and 11 respectively ). Other 
PCR products which did not correspond to either band A or B were observed. No 
clones were found that corresponded to bands C or D.
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Sequencing of clones ( Fig 40)
Clone 8 ( corresponding to band A ) was found to agree exactly with the published 
sequence of 3B-HSD type II exon 3.
Clone 10 ( corresponding to band A ) was found to have two substitutions, an A-> G 
at base 5524 and a T-> C at base 5575.
Clone 9 ( corresponding to band B ) was found to have a single substitution, an A-> G 
at base 5671.
Clone 11 ( corresponding to band B ) was found to have two substitutions, an A-> G 
at base 5671 i.e. the same substitution found in clone 9, and an A-> G at base 5556.
The obvious discrepencies between clones necessitated the further analysis of each 
clone by DGGE. The selection of clones had been based on DGGE analysis using 5' 
GC clamped products. It was decided to further analyse clones 8, 10, 9, and 11 using 
a 3' GC clamp ( Fig 41 ). The 5' GC clamped samples showed the same pattern as 
before i.e. clones 8 and 10 co-migrated with band A, and clones 9 and 11 co-migrated 
with band B. When tested with a 3' GC clamp only clone 8 co-migrated with band A. 
Clone 10 3' GC resolved at a much lower point in the gel. Only clone 9 co-migrated 
with band B as before. Clone 11 resolved at a much lower point in the gel.
Discussion: type II exon 3
The screening of type II exon 3 by DGGE showed no differences in Pfe and Ran 
samples when compared to controls. In family Sta both affected sons ( Sta III-l and 
III-2 ) and their mother ( Sta II-2 ) produced four bands, A, B, C, and D. Two clones 
each of bands A and B were sequenced giving a different result in each case. The
88
clones had originally been selected for sequencing on the basis of DGGE analysis 
using 5'GC clamped products, however, further DGGE analysis using 3GC clamped 
products revealed that clones 10 and 11 were the product of Taq polymerase errors. 
Only clones 8 and 9 co-migrated with bands A and B using both 5' and 3GC clamped 
products and were therefore the only two legitimate clones.
Every sample tested produced band A ( clone 8 ) which has been confirmed as wild 
type 38-HSD type II. Both affected sons and their mother had a second allele ( clone 
9 ) containing an A-> G point mutation at base 5671 ( Fig 40 ). This point mutation 
resulted in the substitution of an Asn for a Ser at codon 100. The substitution at base 
5671 has not been detected in over 30 genes selected from the normal population. It is 
not known at present what effect this amino acid substitution will have on the activity 
of the enzyme.
No clones of bands C or D were observed ( Fig 39 ). Bands C and D were most 
probably heteroduplexes formed by the melting and reannealing of bands A and B 
during the PCR amplification. Although these heteroduplexes were probably 
successfully cloned into pT7 Blue T-vector, subsequent transformation and 
amplification in the host Escherichia coli may have resulted in the repair of the 
mismatch by the host E. colis repair mechanisms. This experiment emphasised the 
problems which may be encountered when sequencing cloned PCR products. Four 
separate clones of 227 bp produced four different results indicating that the error rate 
of Promega Taq polymerase may be much higher than expected.
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Figure 38: DGGE gel showing the m igration of hum an 3B-HSD type II exon 3.
(+) = control patient.
Tracks 1-5 contain sam ples am plified with a 3'GC clam p.
Tracks 6-10 contain sam ples am plified with a 5'GC clam p.
Tracks 2 & 7 = Sta III-l 
Tracks 3 & 8 = Pfe IV-2 
Tracks 4 & 9 = Ran III-3
Bands A, B, C, and D are identified at each side of the gel. The gradient of 
denaturants was 35-65% . The gel was run at 100mA, 80V for 20 hours.
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Figure 39: Selection of positive clones bv DGGE ( Sta III-l: 3B-HSD type II exon 3) 
All samples were am plified using a 5'GC clam p. Track 8 contains Sta III-1 
exon 3 as a positive control. Bands A, B, C, and D are iden tified  at right 
hand side. The gradient of denaturants was 35-65% . The gel w as run at 
100mA, 80V for 20 hours.
Clone 8
Clone 10
A>G T>C
Clone 9 Asn>Ser
A>G
Clone 11
A>G A>G
Figure 40: Clones 8. 10. 9. and Ilf  StaIII-l: 3B-HSD type II exon 31 
Point mutations present in each clone are highlighted.
Clone + 8 1 0  9 1 1 + 8 1 0  9 1 1
C &
Figure 41: Com parison of clones using both 5' and 3' GC clam ps ( Sta III - l:  313-HSD
type II exon 31.
(+) = control patient.
T racks 1-6 contain sam ples am plified w ith a 5 'G C  clam p. T racks 7-12 
contain sam ples am plified with a 3'GC clamp. T racks 4 and 10 contain  Sta 
I I I -1 exon 3 as a positive control. Bands A, B, C, and D are iden tified  at 
each side of the gel. The gradient of denaturants w as 35-65% . T he gel was 
run at 100mA, 80V for 20 hours.
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DGGE screening of 3R-FLSD tvne II exon 4
In the following experiments a large portion of the coding sequence of exon 4 and a 
small amount of flanking non-coding sequence was screened by DGGE. The majority 
of the 3f untranslated sequence was not screened. According to the melt maps (Alb- 
19), the use of primers (m) and (o) to amplify a 5GC clamped fragment would result 
in the screening of bases 8110 - 8270 although bases 7849 - 8110 would remain 
unscreened (A 16). The same PCR product when amplified with a 3GC clamp would 
result in the screening of bases 7849 - 8270 (A17). By using primers (n) and (p) bases 
8181 - 8775 were comprehensively screened (A 18 & 19). In the following results 
nucleotides 7849 - 8270 are referred to as exon 4A. An overlapping fragment of 
nucleotides 8181 - 8775 is referred to as exon 4B.
Results
Using primers (n) and (p) no sequence variations were detected in any of the samples.
When exon 4A was amplified with a 5GC clamp ( primers (m) and (o)), Sta and Pfe 
samples produced a single band which migrated to the same depth in gel as controls. 
The Ran III-3 band, however, migrated to a slightly lower depth in the gel than 
controls ( Fig 42 ). Screening of Ran IE-4, Ran II-7, and Ran II-8 revealed that both 
parents ( Ran II-7 and Ran II-8 ) produced two bands, one band which migrated to the 
same depth in gel as controls ( band A ) and one band which resolved at a slightly 
lower depth in the gel ( band B ). Both sibs, Ran IH-3 and Ran ID-4, only produced 
band B ( Fig 43 ).
The remaining PCR products of Ran III-3, IH-4, II-7, and II-8 were cloned separately 
into pT7 Blue T-vector and putative clones identified by blue/white selection. The 
presence of insert in these clones was confirmed by PCR. PCR products from positive
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clones were run on DGGE alongside Ran controls. In the case of Ran II-7 and Ran II- 
8, clones which co-migrated with bands A and B were selected for sequencing. For 
Ran ni-3 and Ran IE-4, clones which co-migrated with band B were selected. Clones 
which did not co-migrate with the control bands were disregarded.
Sequencing of clones
All clones corresponding to band A showed no sequence variation when compared to 
the published sequence of 3B-HSD type II exon 4.
All clones corresponding to band B revealed a single point mutation T -> G at base 
8118. This point mutation would lead to the substitution of Arg for the wild type Leu 
at codon 173 ( Fig 44). No other sequence variations were found in these clones.
Screening of extended Ran family
All available members of the Ran family were screened for the point mutation at base 
8118. Samples Ran 1-4, II-1, E-6, II-7, and II-8, were all found to possess both bands 
A and B i.e. one normal allele and one mutant allele. Samples Ran 1-2,1-3, II-2, II-3,
II-4, II-5, II-9, 11-10, 11-11, 11-12, 11-13, III-l, III-2, and III-5 only produced the 
normal allele, band A. Samples Ran III-3 and Ran III-4 only produced band B, the 
mutant allele.
The mutation at base 8118 has not been detected in over 40 genes selected from the 
normal population.
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Discussion: type II exon 4
No sequence variations were found in Sta and Pfe samples of 36-HSD type II exon 4.
A single point mutation T-> G at base 8118 was found in several members of the Ran 
family. The effect of the mutation on the melting properties of the PCR fragment was 
quite small. This was expected since the substitution occurs at a transition point 
between two melting domains in the PCR product (A 16). Nevertheless, the effect of 
the mutation was sufficient to distinguish both homozygotes and heterozygotes.
The point mutation was found to be present on both sides of the family, originating 
from Ran 1-1 and Ran 1-4 ( Fig 45 ). This raises the possibility of consanguinity at an 
earlier generation.
The T-> G substitution at base 8118 would lead to the substitution of Arg for the wild 
type Leu at codon 173. As Arg is a hydrophilic, basic amino acid, and Leu is a 
hydrophobic, non-polar amino acid it is probable that this substitution would have a 
marked effect on the activity of the enzyme. Our hypothesis is that this mutation is 
the underlying cause of the 36-HSD deficiency in this family.
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Figure 42: DGGE gel showing the migration of human 3B-HSD type II exon 4A.
(+) = control patient. Tracks 2-4 contain samples Pfe IV-2, Sta III-1, and 
Ran DI-3 respectively. Sample Ran III-3 migrated to a slighdy lower point 
in the gel. The gradient of denaturants was 45-75%. The gel w'as run at 
100mA, 80V for 20 hours.
+ + +
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Figure 43: Analysis of family Ran 38-HSD type II exon 4A bv DGGE.
(+) = control patient. Tracks 2 and 3 contain samples Ran II-7 and Ran II- 
8 respectively. Tracks 5 and 6 contain samples Ran III-3 and Ran III-4 
respectively. Bands A and B are identified at the left hand side of the gel. 
The gradient of denaturants was 45-75%. The gel was run at 100mA, 80V 
for 20 hours.
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Figure 44: Non-svnonvmoiis substitution at codon 173 3B-HSD type II.
Figure 44 shows sequence data outlining the codon substitution at residue 
173. The substitution of a G for a T at base 8118 results in codon 173 
changing from Leu to Arg.
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Automated sequencing of PCR products
To ensure the detection of all possible mutations in the 36-HSD type II gene, 
automated sequencing of PCR products was carried out on affected members of all 
three families ( Ran, Sta, and Pfe). Both the sense and anti-sense strands of each PCR 
product was sequenced. No evidence of mutation was found in any of the patients ( 
data not shown).
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DISCUSSION
Family Ran: A summary of clinical, biochemical, and genetic information on family 
Ran is given in Fig 45 and table 9. When typed for the two genetic polymorphisms in 
exon 4 of the type I gene ( pg47 ) and the microsatellite in intron C of the type II 
gene, the sibs ( Ran III-3 and Ran III-4 ) were found to have inherited the same 
polymorphic alleles from their parents.
Using a combination of DGGE and direct sequencing of PCR products, no evidence 
of mutation could be found in the type I gene, however, a mutation was detected in 
the proximal segment of exon 4 of the type II gene. Sequencing showed the mutation 
to be a single missense mutation of CTA > CGA in codon 173, leading to the 
substitution in the affected patient of arginine for the normal leucine. No other 
sequence variations were found in 3B-HSD type II. The 173 Arg codon is not found in 
the gene for 3B HSD type I and cannot therefore be the product of a gene conversion 
event between the type I and the type II genes. Figure 45 shows that the polymorphic 
markers in 3B HSD type I and type II co-segregate, together with the mutation in 
codon 173 of the type II gene. No recombination events were observed between these 
markers in family Ran.
Insufficient is known at present of the protein structure to predict what effect this 
substitution may have on the activity of the enzyme, however as Arg is a positively 
charged hydrophilic amino acid and leu is a strongly hydrophobic amino acid it is 
probable that the substitution would have an effect on enzyme activity. Neither of the 
sibs homozygous for the codon 173 substitution show disturbances of 
mineralocorticoid or glucocorticoid metabolism, indicating that the main effect of the 
substitution is to reduce the conversion of C19 substrates to androstenedione and 
testosterone, leaving substantially unaffected the conversion of C21 substrates to 
progesterone and 17 alpha hydroxyprogesterone. The type II codon 173 mutation is
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therefore most likely to result in a partial, substrate specific loss of enzyme activity. 
Whether the kinetic effects of the 173Leu-*Arg mutation are limited to A5 substrates 
that are precursors to the sex steroid pathway, or if it also exerts an effect on 
mineralocorticoid or glucocorticoid synthesis, should emerge from work in progress 
on the expression of the allele in vitro.
It is clear that homozygosity of the mutant allele results in the grossly abnormal 
steroid profile exhibited by Ran ni-3 and Ran III-4, however biochemical and clinical 
data suggest that the codon 173 mutation may also exert an affect on members of the 
family heterozygous for the substitution. The mother ( Ran II-7 ) and father ( Ran II-8 
) of the affected sibs exhibited abnormal levels of 36-HSD metabolites suggestive of 
36-HSD deficiency. In addition, Ran II-7 exhibited particularly infrequent and 
irregular periods, on average 1-2 periods a year only lasting 2-7 days. Although Ran
III-3 was conceived spontaneously, Ran III-4 was conceived with the help of 
clomiphene therapy. Ran II-7 has recently been diagnosed as menopausal at the age of 
31 years and is currently on hormone replacement therapy. Steroid analysis of Ran II- 
1 showed no abnormality in the levels of A5 steroids, however, she had previously 
undergone a radical hysterectomy and was effectively post-menopausal. Prior to the 
hysterectomy she had exhibited menstrual irregularities similar to Ran II-7. Ran II-6 
has no history of menstrual irregularities though steroid analysis revealed levels of A5 
steroids indicative of a 36-HSD deficiency. The paternal grandmother ( Ran 1-4 ) of 
the affected sibs was post menopausal and had reduced adrenal function, therefore no 
conclusions about her status could be drawn from steroid analysis. Ran 1-4 had no 
history of menstrual irregularities or fertility problems. The elevated levels in serum 
of the A4 steroids androstenedione in the mother ( Ran II-7 ) and of progesterone, 17- 
hydroxyprogesterone and androstenedione in the propositus ( Ran IE-3 ), her sister ( 
Ran III-4 ) and their father ( Ran II-8 ) have been reported in other cases of 
biochemically-diagnosed 36-HSD deficiency. It is beleived that the increased levels
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of A5 steroids entering the blood from the adrenals and ovaries leads to greater 
conversion of A5 to A4 steroids through the activity of 36-HSD in peripheral tissues.
As 36-HSD is a relatively rare condition, the identification of the same mutation 
originating from both sides of the family was an unexpected result. Family histories 
over 4 generations revealed no evidence of consanguinity.
Family Pfe: Screening of the 36-HSD type I and type II genes by DGGE and direct 
sequencing of PCR products showed no evidence of mutation in the coding sequence 
of either gene. The only point mutation observed was present in the non-coding exon 
1 of 36-HSD type I. When this mutation was used in conjunction with the 
microsatellite in intron C of 36-HSD type II it was conclusively shown that the 
disease phenotype did not co-segregate with either the 36-HSD type I or type II genes 
(F ig 46).
Since the diagnosis of 36-HSD deficiency has been based on clinical and biochemical 
criteria, without access to tissue samples, it is possible that the hirsutism in family Pfe 
may be the result of mutations in an as yet undiscovered 36-HSD. 36-HSD enzyme 
activity is expressed in other mammalian tissues and distinct genes have been cloned 
from rat and mouse (Zhao et al. 1990; Bain et al. 1991; Zhao et al. 1991) that are 
expressed in liver and are members of the 36-HSD family. In the human, similar 
additional isoforms of the enzyme have yet to be defined. Southern blots of human 
genomic DNA ( Fig 13 and Lachance et al. 1990 ) and DGGE ( Figs 30 & 36 ) have 
provided evidence for the existence of several isoforms of 36-HSD in humans 
however the chromosomal location of these sequences is not yet known. SI protection 
studies on RNA expression (Rheaume et al. 1991) and the expression of 36-HSD 
epitopes detected with monoclonal antibodies (Nickson et al. 1990) have shown that 
the type I and type II enzymes are not significantly expressed in tissues other than 
trophoblast, adrenals, gonads, and skin. The existence of additional isoforms of 36-
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HSD would explain why 38-HSD enzyme activity is expressed in other tissues such 
as the liver. It remains a possibility however that the 38-HSD activity detected in the 
liver is the result of another unrelated dehydrogenase enzyme.
The allocation of 38-HSD type I to chromosome lpl3.1 by in situ hybridisation 
(Berube et al. 1989; Morrison et al. 1990) showed no evidence to suggest the 
presence of 38-HSD homologues elsewhere in the genome. If there is a tightly 
clustered gene family of 38-HSD at lpl3 then the markers used in the typing of the 
type I and type II genes strongly suggest that the hirsutism in family Pfe is not the 
result of a 38-HSD deficiency.
When compared to the other families in this study ( Ran and Sta) family Pfe differed 
in various aspects. The mode of inheritance in family Pfe appeared to be dominant, 
although sex linkage could not be ruled out. This may be tested by typing the family 
with a panel of X chromosome polymorphic markers. The mode of inheritance in 
families Ran and Sta was clearly autosomal recessive. In addition, affected members 
of family Pfe had normal basal levels of A5 steroids in serum. Marked elevation of A5 
steroids and their precursors only occurred after ACTH stimulation. This was in 
marked contrast to the steroid profiles of family Ran and family Sta. In these families 
elevated basal levels of A5 steroids and their precursors was observed. The hirsutism 
in family Pfe and the exaggerated response to ACTH stimulation may be due to a 
variety of factors other than 38-HSD deficiency. It is possible that a deficiency exists 
in the catabolism of A5 steroids in family Pfe. Insufficient conversion of circulating 
androgens to oestrogens by the enzyme aromatase may also be a factor. Future work 
on family Pfe may include the use of genetic markers in candidate genes such as 
aromatase in an attempt to establish linkage.
The findings in family Pfe have important implications for the future diagnosis of 38- 
HSD deficiency. Reports on the prevalence of 38-HSD deficiency in women with
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symptoms of androgen excess vary between 9 and 61% ( Zerah et al. 1991). As many 
diagnoses have been based on steroid profiles similar to that found in family Pfe it is 
possible that 36-HSD deficiency is not as common as some may believe.
Family Sta: A summary of the clinical and genetic information in family Sta is given 
in figure 47. When typed for the two genetic polymorphisms in exon 4 of the type I 
gene ( p47 ) and the micro satellite in intron C of the type II gene it was shown that 
both affected sons inherited the same polymorphic alleles from either parent. The 
same genetic markers also revealed evidence of a possible crossover between the 36- 
HSD type I and type II genes on the fathers side of the family.
Screening of the type I gene by DGGE revealed no evidence of mutation. Screening 
of the type II gene by DGGE revealed a mutation in exon 3 of the type II gene. 
Sequencing showed the mutation to be a single missense mutation of AAT->AGT in 
codon 100 leading to the substitution of Ser for the normal Asn. No other sequence 
variations were found in 36-HSD type II. The Ser codon is not found in the gene for 
36-HSD type I and cannot therefore be the product of a typefc>type II gene conversion 
event. The substitution was detected in both affected sibs and also in their mother. No 
other members of the family possessed the substitution, including Sta II-1 who is 
affected with hirsutism. If the Asn>Ser substitution is involved in the manifestation of 
MPH in the two sibs then it would appear that Sta II-1 is a sporadic case.
Insufficient is known at present of the protein structure to predict what effect the 
substitution may have on the activity of the enzyme. Both Ser and Asn have a neutral 
charge though Ser is slightly more hydrophobic. Though the main defect in family Sta 
is in the conversion of C l9 substrates to androstenedione and testosterone, it appears 
that the conversion of the C21 substrates to progesterone and 17 alpha 
hydroxyprogesterone is also affected as Sta III-2 demonstrated an impaired cortisol
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response to synacthen. The expression of the mutant allele is currently under test in 
vitro.
To date no evidence of mutation has been detected in either the 36-HSD type I or 36- 
HSD type II genes of the father in family Sta. As mentioned previously it remains a 
possibility that a deficiency exists in an as yet undiscovered 36-HSD gene though the 
results of both HCG and synacthen tests suggest that both the testes and the adrenals 
are affected. This means that 36-HSD type II is still the most likely source of a 
deficiency. The possibility that a mutation may still lie undetected in either the coding 
sequence or even in a 5' or 3' regulatory region of the fathers type II gene is currently 
under investigation.
The aim of this thesis was primarily to detect the underlying genetic factors which 
result in 36-HSD deficiency, however, the polymorphic markers discovered during 
the course of this work and the techniques which have been employed will prove 
useful in other areas. The polymorphic markers can be used to build up a more 
detailed genetic map in the region of chromosome lpl-2. Analysis of polymorphic 
markers ( Figs 45, 46, and 47 ) has demonstrated significant genetic linkage between 
the genes for 36-HSD types I and II. When the LOD scores for each of the families 
presented in this report were added to those of families 1 and 2 from Rheaume et al. 
1992, a combined score of 5.374 was obtained, indicating a high probability of tight 
linkage. At present the physical linkage between the two loci has not been 
determined, nor have the linkage relationships with other members of the putative 
gene family been determined. It is hoped that the use of somatic cell hybrids may 
allow the mapping of 36-HSD homologues, detected by DGGE ( Figs 30 & 36 ), to 
chromosome lpl-2. The possibility of a tightly clustered gene family raises the 
possibility that in some cases of 36-HSD deficiency mutations may be due to unequal 
crossing over or to gene conversion, as has been observed for aldosterone synthase 
and 116-hydroxylase (Lifton et al. 1992) and in several other gene clusters including
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21-hydroxylase (Donohoue et al. 1986; Garlepp et al. 1986; Harada et al. 1987). This 
hypothesis is unlikely to apply to the families presented in this thesis as only single 
point mutations were observed, however, as it is not known what other homologous 
elements may be clustered on chromosome 1, the possibility cannot be ruled out.
A study of the genetic basis of inherited breast cancer is currently underway which 
will also utilise the polymorphic markers in 36-HSD. The existence of families with 
raised incidences of breast cancer has long been recognised and is currently the focus 
of considerable work to find the genes responsible (Schildkraut 1989; Hall 1990; 
Lynch 1990; Ponder 1990; Claus 1991). Results from the breast cancer consortium 
indicate that about one third of families result from a predisposition due to a locus on 
chromosome 17q. These families have a mixture of breast and ovarian cancer. In 
other families, with breast cancer alone, the disease is clearly not linked to 17q. 
Current work to look for predisposing genes elsewhere in the genome focuses on 
segregation studies of DNA which map in the main to those parts of the genome 
where cytogenetic abnormalities have been detected or where oncogenes or anti­
oncogenes are located. The chromosomal location of 36-HSD ( lpl3.1 ) is of interest 
as Nras maps to the same region. Ipl3 is also one of the commonest sites for 
cytogenetic abnormalities in breast cancer. Mapping studies have not so far given a 
clear positive linkage to this region, studies are limited by a lack of good polymorphic 
markers and possible genetic heterogeneity. The use of the polymorphic markers 
presented in this thesis may prove to be a significant step in establishing linkage.
It is possible that 36-HSD may play a direct role in the incidence of breast cancer. 
Several lines of evidence indicate that sex hormones influence the management and 
incidence of breast cancer (Henderson 1981; Key 1988; Bulbrook 1989) and it has 
been suggested that genetic variation in sex hormone receptors or in the enzymes 
involved in steroid biosynthesis, e.g. 38-HSD, may contribute to the risk of breast 
cancer by changing effective local steroid hormone concentrations at particular stages
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of development. Candidate genes and their known polymorphic markers are shown in 
Table 10. DGGE will prove useful in the detection of polymorphic markers in genes 
for which so far none have been reported.
Table 10
ENZYME NAME | MAP DATA | ALLELE SYSTEM
Cholesterol side chain cleavage 
(P450scc)
15q21 1 (CA)n repeat
Aromatase (P450Arom) 15q21.1 (CA)n repeat
17-alpha hydroxylase (P450 17c) 10 -
36 hydroxysteroid 
dehydrogenaseAsomerase (36HSD)
lpl3.1 1 intragenic RFLP 
1 intragenic substitution 
1 microsatellite
176-hydroxy steroid dehydrogenase 
(176-HSD)
17q -
Steroid sulphatase (STS) Xp22.3 (CA)n repeat in GMGX9 
within 600kb of STS
Oestrogen receptor (ESR) 6q24-27 3 RFLP 
1 intragenic substitution
Androgen receptor (AR) Xql2 (CAG)n intragenic repeat
I l l
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APPENDIX
Melt mans
The following pages contain the melting profiles of each region of the 36-HSD type I 
and type II genes calculated using the MELT programmes of Lerman and Silverstein ( 
1987 ). The melting information gained from these graphs was used to determine the 
denaturing gradient conditions and electrophoresis times that would result in 
maximum resolution in the gel of DNA fragments differing by single base changes.
A detailed description of the use of melt maps and their application to DGGE is given 
by Lerman and Silverstein ( 1987 ).
A plot of Tm as a function of position along a DNA molecule is called a melting map. 
The computer analysis is based on the assumption that each base pair in a molecule of 
DNA can exist in only two possible states; either stacked , helical, and hydrogen 
bonded, or unstacked, disordered and without base pairing i.e. melted. The existence 
of fairly long regions, 30-300bp, termed domains, at which all bases melt at very 
nearly the same temperature is typical. The melting maps shown in the following 
pages show the positions and Tms of melting domains in each fragment of DNA 
based on its nucleotide sequence. Also shown are a series of plots which calculate the 
difference in migration rates through the denaturing gradient between the fully base 
paired helix and molecules with single mismatches as a function of time after starting 
electrophoresis. DGGE is most effective when detecting mutations in the lowest 
melting domain of the DNA molecule. The calculations are based on a gel 
temperature of 60°C. Time ( Tk ) and displacement are given in arbitrary units, 
approximately equal to hours and millimetres respectively.
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Melting contour plot across sequence 3B-HSD type I exon 4B 5'GC
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Melting contour plot across sequence 31WHSD tvne I exon 4B 3'GC
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VIeltinp contour plot across sequence 3R-HSD type II exon 1/2 5'GC
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Melting contour plot across sequence 3R-HSD type II exon 1/2 3'GC
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Melting contour plot across sequence 3B-HSD type II exon 3 5'GC
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Vfeltiny contour plot across sequence 3B-HSD type IT exon 3 3'GC
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Melting contour plot across sequence 3R-HSD type II exon 4A 5'GC
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VTeltiny contour nlot across sennenre 3K-HSD tvne TT exon 4 A  3fGC
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Displacement caused bv single mismatches
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VIelting contour nlot across sequence 3R-HSD tvne IT exon 4B 5'GC
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Melting contour plot across sequence 3B-HSD type II exon 4B 3'GC
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